

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

**EP 1 166 798 A1**

(12)

**EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
**02.01.2002 Bulletin 2002/01**

(51) Int Cl.7: **A61K 45/06**

(21) Application number: **00250194.8**

(22) Date of filing: **23.06.2000**

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE**  
Designated Extension States:  
**AL LT LV MK RO SI**

(71) Applicant: **Schering Aktiengesellschaft  
13353 Berlin (DE)**

(72) Inventors:  
• **Siemeister, Gerhard  
13503 Berlin (DE)**  
• **Haberey, Martin, Dr.  
12169 Berlin (DE)**  
• **Thierauch, Karl-Heinz, Dr.  
14169 Berlin (DE)**

(54) **Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/ Tie receptor function and their use**

(57) The present invention describes the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF) and VEGF receptor

systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

**EP 1 166 798 A1**

## Description

**[0001]** The present invention provides the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

**[0002]** Protein ligands and receptor tyrosine kinases that specifically regulate endothelial cell function are substantially involved in physiological as well as in disease-related angiogenesis. These ligand/receptor systems include the Vascular Endothelial Growth Factor (VEGF) and the Angiopoietin (Ang) families, and their receptors, the VEGF receptor family and the tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (Tie) family. The members of the two families of receptor tyrosine kinases are expressed primarily on endothelial cells. The VEGF receptor family includes Flt1 (VEGF-R1), Flk1/KDR (VEGF-R2), and Flt4 (VEGF-R3). These receptors are recognized by members of the VEGF-related growth factors in that the ligands of Flt1 are VEGF and placenta growth factor (PlGF), whereas Flk1/KDR binds VEGF, VEGF-C and VEGF-D, and the ligands of Flt4 are VEGF-C and VEGF-D (Nicosia, Am. J. Pathol. 153, 11-16, 1998). The second family of endothelial cell specific receptor tyrosine kinases is represented by Tie1 and Tie2 (also known as Tek). Whereas Tie1 remains an orphan receptor, three secreted glycoprotein ligands of Tie2, Ang1, Ang2, and Ang3/Ang4 have been discovered (Davis et al., Cell 87, 1161-1169, 1996; Maisonpierre et al., Science 277, 55-60, 1997; Valenzuela et al., Proc. Natl. Acad. Sci. USA 96, 1904-1909, 1999; patents: US 5,521,073; US 5,650,490; US 5,814,464).

**[0003]** The pivotal role of VEGF and of its receptors during vascular development was exemplified in studies on targeted gene inactivation. Even the heterozygous disruption of the VEGF gene resulted in fatal deficiencies in vascularization (Carmeliet et al., Nature 380, 435-439, 1996; Ferrara et al., Nature 380, 439-442, 1996). Mice carrying homozygous disruptions in either Flt1 or Flk1/KDR gene die in mid-gestation of acute vascular defects. However, the phenotypes are distinct in that Flk1/KDR knock-out mice lack both endothelial cells and a developing hematopoietic system (Shalaby et al. Nature 376, 62-66, 1995), whereas Flt1 deficient mice have normal hematopoietic progenitors and endothelial cells, which fail to assemble into functional vessels (Fong et al., 376, 66-70, 1995). Disruption of the Flt4 gene, whose extensive embryonic expression becomes restricted to lymphatic vessels in adults, revealed an essential role of Flt4 for the remodeling and maturation of the primary vascular networks into larger blood vessels during early development of the cardiovascular system (Dumont et al., Science 282, 946-949, 1998). Consistent with the lymphatic expression of Flt4 in adults overexpression of VEGF-C in the skin of transgenic mice resulted in lymphatic, but not vascular, endothelial proliferation and vessel enlargement (Jeltsch et al., Science 276, 1423-1425, 1997). Moreover, VEGF-C was reported to induce neovascularization in mouse cornea and chicken embryo chorioallantoic membrane models of angiogenesis (Cao et al., Proc. Natl. Acad. Sci. USA 95, 14389-14394, 1998).

**[0004]** The second class of endothelial cell specific receptor tyrosine kinases has also been found to be critically involved in the formation and integrity of vasculature. Mice deficient in Tie1 die of edema and hemorrhage resulting from poor structural integrity of endothelial cells of the microvasculature (Sato et al., Nature 376, 70-74, 1995; Rodewald & Sato, Oncogene 12, 397-404, 1996). The Tie2 knock-out phenotype is characterized by immature vessels lacking branching networks and lacking periendothelial support cells (Sato et al., Nature 376, 70-74, 1995; Dumont et al., Genes Dev. 8, 1897-1909, 1994). Targeted inactivation of the Tie2 ligand Ang1, as well as overexpression of Ang2, an inhibitory ligand, resulted in phenotypes similar to the Tie2 knock out (Maisonpierre et al., Science 277, 55-60, 1997; Suri et al., Cell 87, 1171-1180). Conversely, increased vascularization was observed upon transgenic overexpression of Ang1 (Suri et al., Science 282, 468-471, 1998; Thurston et al., Science 286, 2511-2514, 1999).

**[0005]** The results from angiogenic growth factor expression studies in corpus luteum development (Maisonpierre et al., Science 277, 55-60, 1997; Goede et al. Lab. Invest. 78, 1385-1394, 1998), studies on blood vessel maturation in the retina (Alon et al., Nature Med. 1, 1024-1028, 1995; Benjamin et al. Development 125, 1591-1598, 1998), and gene targeting and transgenic experiments on Tie2, Ang1, and Ang2, suggest a fundamental role of the Angiopoietin/Tie receptor system in mediating interactions between endothelial cells and surrounding pericytes or smooth muscle cells. Ang1, which is expressed by the periendothelial cells and seems to be expressed constitutively in the adult, is thought to stabilize existing mature vessels. Ang2, the natural antagonist of Ang1 which is expressed by endothelial cells at sites of vessel sprouting, seems to mediate loosening of endothelial-periendothelial cell contacts to allow vascular remodeling and sprouting in cooperation with angiogenesis initiators such as VEGF, or vessel regression in the absence of VEGF (Hanahan, Science 277, 48-50, 1997).

**[0006]** In pathological settings associated with aberrant neovascularization elevated expression of angiogenic growth factors and of their receptors has been observed. Most solid tumors express high levels of VEGF and the VEGF receptors appear predominantly in endothelial cells of vessels surrounding or penetrating the malignant tissue (Plate et al., Cancer Res. 53, 5822-5827, 1993). Interference with the VEGF/VEGF receptor system by means of VEGF-neutralizing antibodies (Kim et al., Nature 362, 841-844, 1993), retroviral expression of dominant negative VEGF receptor variants (Millauer et al., Nature 367, 576-579, 1994), recombinant VEGF-neutralizing receptor variants (Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998), or small molecule inhibitors of VEGF receptor tyrosine

kinase (Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000), or targeting cytotoxic agents via the VEGF/VEGF receptor system (Arora et al., Cancer Res. 59, 183-188, 1999; EP 0696456A2) resulted in reduced tumor growth and tumor vascularization. However, although many tumors were inhibited by interference with the VEGF/VEGF receptor system, others were unaffected (Millauer et al., Cancer Res. 56, 1615-1620, 1996). Human tumors as well as experimental tumor xenografts contain a large number of immature blood vessels that have not yet recruited periendothelial cells. The fraction of immature vessels is in the range of 40% in slow growing prostate cancer and 90% in fast growing glioblastoma. A selective obliteration of immature tumor vessels was observed upon withdrawal of VEGF by means of downregulation of VEGF transgene expression in a C6 glioblastoma xenograft model. This result is in accordance with a function of VEGF as endothelial cell survival factor. Similarly, in human prostate cancer shutting off VEGF expression as a consequence of androgen-ablation therapy led to selective apoptotic death of endothelial cells in vessels lacking periendothelial cell coverage. In contrast, the fraction of vessels which resisted VEGF withdrawal showed periendothelial cell coverage (Benjamin et al., J. Clin. Invest. 103, 159-165, 1999).

[0007] The observation of elevated expression of Tie receptors in the endothelium of metastatic melanomas (Kai-painen et al., Cancer Res. 54, 6571-6577, 1994), in breast carcinomas (Salvén et al., Br. J. Cancer 74, 69-72, 1996), and in tumor xenografts grown in the presence of dominant-negative VEGF receptors (Millauer et al., Cancer Res. 56, 1615-1620, 1996), as well as elevated expression of Flt4 receptors in the endothelium of lymphatic vessels surrounding lymphomas and breast carcinomas (Jussila et al., Cancer Res. 58, 1599-1604, 1998), and of VEGF-C in various human tumor samples (Salvén et al., Am. J. Pathol. 153, 103-108, 1998), suggested these endothelium-specific growth factors and receptors as candidate alternative pathways driving tumor neovascularization. The high upregulation of Ang2 expression already in early tumors has been interpreted in terms of a host defense mechanism against initial cooption of existing blood vessels by the developing tumor. In the absence of VEGF, the coopted vessels undergo regression leading to necrosis within the center of the tumor. Contrarily, hypoxic upregulation of VEGF expression in cooperation with elevated Ang2 expression rescues and supports tumor vascularization and tumor growth at the tumor margin (Holash et al., Science 284, 1994-1998, 1999; Holash et al., Oncogene 18, 5356-5362, 1999).

[0008] Interference with Tie2 receptor function by means of Angiopoietin-neutralizing Tie2 variants consisting of the extracellular ligand-binding domain has been shown to result in inhibition of growth and vascularization of experimental tumors (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al. Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Comparing the effects of interference with the endothelium-specific receptor tyrosine kinase pathways by means of paracrine expression of the respective extracellular receptor domains on the same cellular background demonstrated inhibition of tumor growth upon blockade of the VEGF receptor system and of the Tie2 receptor system, respectively (Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

It is known that the inhibition of the VEGF/VEGR receptor system by various methods resulted only in slowing down growth of most experimental tumors (Millauer et al., Nature 367, 576-579, 1994; Kim et al., Nature 362, 841-844, 1993; Millauer et al., Cancer Res. 56, 1615-1620, 1996; Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998; Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Even by escalation of therapeutic doses a plateau level of therapeutic efficacy was achieved (Kim et al., Nature 362, 841-844, 1993; Wood et al. Cancer Res. 60, 2178-2189, 2000). Similar results were observed upon interference with the Angiopoietin/Tie2 receptor system (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al., Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

[0009] However, there is a high demand for methods that enhance the therapeutic efficacy of anti-angiogenous compounds.

[0010] Searching for methods that enhance the therapeutic efficacy of anti-angiogenic compounds, superior anti-tumor effects were observed unexpectedly upon combination of inhibition of VEGF/VEGF receptor systems and interference with biological function of Angiopoietin/Tie receptor systems. The mode of action underlying the superior effects observed may be that interference biological function of Angiopoietin/Tie receptor systems destabilizes endothelial cell-periendothelial cell interaction of existing mature tumor vessels and thereby sensitizes the endothelium to compounds directed against VEGF/VEGF receptor systems.

[0011] Based on this unexpected finding the present invention provides the combination of functional interference with VEGF/VEGF receptor systems and with Angiopoietin/Tie receptor systems for inhibition of vascularization and of tumor growth.

The pharmaceutical composition consists of two components: compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of VEGF/VEGF receptor systems. Compound II interferes with the biological function of one or several of Angiopoietin/Tie receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of Angiopoietin/Tie receptor systems. Alternatively, compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems and compound II consists of cytotoxic

agents which are targeted to the endothelium via recognition of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems. Targeting or modulation of the biological activities of VEGF/VEGF receptor systems and of Angiopoietin/Tie receptor systems can be performed by

- 5 (a) compounds which inhibit receptor tyrosine kinase activity,
- (b) compounds which inhibit ligand binding to receptors,
- (c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- (d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- (e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/
- 10 VEGF receptor or Angiopoietin/Tie receptor systems,
- (f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

15 **[0012]** A compound comprised by compositions of the present invention can be a small molecular weight substance, an oligonucleotide, an oligopeptide, a recombinant protein, an antibody, or conjugates or fusionproteins thereof. An example of an inhibitor is a small molecular weight molecule which inactivates a receptor tyrosine kinase by binding to and occupying the catalytic site such that the biological activity of the receptor is decreased. Kinase inhibitors are known in the art (Sugen: SU5416, SU6668; Fong et al. (1999), Cancer Res. 59, 99-106; Vajkoczy et al., Proc. Am.

20 Associ. Cancer Res. San Francisco (2000), Abstract ID 3612; Zeneca: ZD4190, ZD6474; Wedge et al. (2000), Cancer Res. 60, 970-975; Parke-Davis PD0173073, PD0173074; Johnson et al., Proc. Am. Associ. Cancer Res., San Francisco (2000), Abstract ID 3614; Dimitroff et al. (1999), Invest. New Drugs 17, 121-135). An example of an antagonist is a recombinant protein or an antibody which binds to a ligand such that activation of the receptor by the ligand is prevented.

25 Another example of an antagonist is an antibody which binds to the receptor such that activation of the receptor is prevented. An example of an expression modulator is an antisense RNA or ribozyme which controls expression of a ligand or a receptor. An example of a targeted cytotoxic agent is a fusion protein of a ligand with a bacterial or plant toxin such as Pseudomonas exotoxin A, Diphtheria toxin, or Ricin A. An example of a targeted coagulation-inducing agent is a conjugate of a single chain antibody and tissue factor. Ligand-binding inhibitors such as neutralizing antibodies which are known in the art are described by Genentech (rhuMAbVEGF) and by Presta et al. (1997), Cancer

30 Res. 57, 4593-4599. Ligand-binding receptor domains are described by Kendall & Thomas (1993), Proc. Natl. Acad. Sci., U.S.A.90, 10705-10709; by Goldman et al. (1998) Proc. Natl. Acad. Sci., U.S.A.95, 8795-8800 and by Lin et al. (1997), J. Clin. Invest. 100, 2072-2078. Further, dominant negative receptors have been described by Millauer et al. (1994), Nature 367, 567-579.

Receptor blocking antibodies have been described by Imclone (c-p1C11, US 5,874,542). Further known are antagonistic ligand mutants (Siemeister et al. (1998), Proc. Natl. Acad. Sci., U.S.A.95, 4625-4629). High affinity ligand- or receptor binding oligo nucleotides have been described by NeXstar (NX-244) and Drolet et al. (1996), Nat. Biotech 14, 1021-1025. Further, small molecules and peptides have been described.


**[0013]** Expression regulators have been described as anti-sense oligo nucleotides and as ribozymes (RPI, Angiozyme™, see RPI Homepage).

40 **[0014]** Examples for delivery-/Targeting-Systems have been described as ligand/ antibody-toxin-fusion-proteins or conjugates (Arora et al. (1999), Cancer Res. 59, 183-188 and Olson et al. (1997), Int. J. Cancer 73, 865-870), as endothel cell targeting of liposomes (Spragg et al. (1997), Prog. Natl. Acad. Sci, U.S.A.94, 8795-8800, and as endothel cell targeting plus coagulation-induction (Ran et al., (1998), Cancer Res. 58, 4646-4653).

45 **[0015]** Small molecules which inhibit the receptor tyrosine kinase activity are for example molecules of general formula I

50

55



in which


- 20
- 25
- 30
- 35
- 40
- 45
- 50
- 55
- 60
- 65
- 70
- 75
- 80
- 85
- 90
- 95
- 100
- 105
- 110
- 115
- 120
- 125
- 130
- 135
- 140
- 145
- 150
- 155
- 160
- 165
- 170
- 175
- 180
- 185
- 190
- 195
- 200
- 205
- 210
- 215
- 220
- 225
- 230
- 235
- 240
- 245
- 250
- 255
- 260
- 265
- 270
- 275
- 280
- 285
- 290
- 295
- 300
- 305
- 310
- 315
- 320
- 325
- 330
- 335
- 340
- 345
- 350
- 355
- 360
- 365
- 370
- 375
- 380
- 385
- 390
- 395
- 400
- 405
- 410
- 415
- 420
- 425
- 430
- 435
- 440
- 445
- 450
- 455
- 460
- 465
- 470
- 475
- 480
- 485
- 490
- 495
- 500
- 505
- 510
- 515
- 520
- 525
- 530
- 535
- 540
- 545
- 550
- 555
- 560
- 565
- 570
- 575
- 580
- 585
- 590
- 595
- 600
- 605
- 610
- 615
- 620
- 625
- 630
- 635
- 640
- 645
- 650
- 655
- 660
- 665
- 670
- 675
- 680
- 685
- 690
- 695
- 700
- 705
- 710
- 715
- 720
- 725
- 730
- 735
- 740
- 745
- 750
- 755
- 760
- 765
- 770
- 775
- 780
- 785
- 790
- 795
- 800
- 805
- 810
- 815
- 820
- 825
- 830
- 835
- 840
- 845
- 850
- 855
- 860
- 865
- 870
- 875
- 880
- 885
- 890
- 895
- 900
- 905
- 910
- 915
- 920
- 925
- 930
- 935
- 940
- 945
- 950
- 955
- 960
- 965
- 970
- 975
- 980
- 985
- 990
- 995
- 1000
- 1005
- 1010
- 1015
- 1020
- 1025
- 1030
- 1035
- 1040
- 1045
- 1050
- 1055
- 1060
- 1065
- 1070
- 1075
- 1080
- 1085
- 1090
- 1095
- 1100
- 1105
- 1110
- 1115
- 1120
- 1125
- 1130
- 1135
- 1140
- 1145
- 1150
- 1155
- 1160
- 1165
- 1170
- 1175
- 1180
- 1185
- 1190
- 1195
- 1200
- 1205
- 1210
- 1215
- 1220
- 1225
- 1230
- 1235
- 1240
- 1245
- 1250
- 1255
- 1260
- 1265
- 1270
- 1275
- 1280
- 1285
- 1290
- 1295
- 1300
- 1305
- 1310
- 1315
- 1320
- 1325
- 1330
- 1335
- 1340
- 1345
- 1350
- 1355
- 1360
- 1365
- 1370
- 1375
- 1380
- 1385
- 1390
- 1395
- 1400
- 1405
- 1410
- 1415
- 1420
- 1425
- 1430
- 1435
- 1440
- 1445
- 1450
- 1455
- 1460
- 1465
- 1470
- 1475
- 1480
- 1485
- 1490
- 1495
- 1500
- 1505
- 1510
- 1515
- 1520
- 1525
- 1530
- 1535
- 1540
- 1545
- 1550
- 1555
- 1560
- 1565
- 1570
- 1575
- 1580
- 1585
- 1590
- 1595
- 1600
- 1605
- 1610
- 1615
- 1620
- 1625
- 1630
- 1635
- 1640
- 1645
- 1650
- 1655
- 1660
- 1665
- 1670
- 1675
- 1680
- 1685
- 1690
- 1695
- 1700
- 1705
- 1710
- 1715
- 1720
- 1725
- 1730
- 1735
- 1740
- 1745
- 1750
- 1755
- 1760
- 1765
- 1770
- 1775
- 1780
- 1785
- 1790
- 1795
- 1800
- 1805
- 1810
- 1815
- 1820
- 1825
- 1830
- 1835
- 1840
- 1845
- 1850
- 1855
- 1860
- 1865
- 1870
- 1875
- 1880
- 1885
- 1890
- 1895
- 1900
- 1905
- 1910
- 1915
- 1920
- 1925
- 1930
- 1935
- 1940
- 1945
- 1950
- 1955
- 1960
- 1965
- 1970
- 1975
- 1980
- 1985
- 1990
- 1995
- 2000
- 2005
- 2010
- 2015
- 2020
- 2025
- 2030
- 2035
- 2040
- 2045
- 2050
- 2055
- 2060
- 2065
- 2070
- 2075
- 2080
- 2085
- 2090
- 2095
- 2100
- 2105
- 2110
- 2115
- 2120
- 2125
- 2130
- 2135
- 2140
- 2145
- 2150
- 2155
- 2160
- 2165
- 2170
- 2175
- 2180
- 2185
- 2190
- 2195
- 2200
- 2205
- 2210
- 2215
- 2220
- 2225
- 2230
- 2235
- 2240
- 2245
- 2250
- 2255
- 2260
- 2265
- 2270
- 2275
- 2280
- 2285
- 2290
- 2295
- 2300
- 2305
- 2310
- 2315
- 2320
- 2325
- 2330
- 2335
- 2340
- 2345
- 2350
- 2355
- 2360
- 2365
- 2370
- 2375
- 2380
- 2385
- 2390
- 2395
- 2400
- 2405
- 2410
- 2415
- 2420
- 2425
- 2430
- 2435
- 2440
- 2445
- 2450
- 2455
- 2460
- 2465
- 2470
- 2475
- 2480
- 2485
- 2490
- 2495
- 2500
- 2505
- 2510
- 2515
- 2520
- 2525
- 2530
- 2535
- 2540
- 2545
- 2550
- 2555
- 2560
- 2565
- 2570
- 2575
- 2580
- 2585
- 2590
- 2595
- 2600
- 2605
- 2610
- 2615
- 2620
- 2625
- 2630
- 2635
- 2640
- 2645
- 2650
- 2655
- 2660
- 2665
- 2670
- 2675
- 2680
- 2685
- 2690
- 2695
- 2700
- 2705
- 2710
- 2715
- 2720
- 2725
- 2730
- 2735
- 2740
- 2745
- 2750
- 2755
- 2760
- 2765
- 2770
- 2775
- 2780
- 2785
- 2790
- 2795
- 2800
- 2805
- 2810
- 2815
- 2820
- 2825
- 2830
- 2835
- 2840
- 2845
- 2850
- 2855
- 2860
- 2865
- 2870
- 2875
- 2880
- 2885
- 2890
- 2895
- 2900
- 2905
- 2910
- 2915
- 2920
- 2925
- 2930
- 2935
- 2940
- 2945
- 2950
- 2955
- 2960
- 2965
- 2970
- 2975
- 2980
- 2985
- 2990
- 2995
- 3000
- 3005
- 3010
- 3015
- 3020
- 3025
- 3030
- 3035
- 3040
- 3045
- 3050
- 3055
- 3060
- 3065
- 3070
- 3075
- 3080
- 3085
- 3090
- 3095
- 3100
- 3105
- 3110
- 3115
- 3120
- 3125
- 3130
- 3135
- 3140
- 3145
- 3150
- 3155
- 3160
- 3165
- 3170
- 3175
- 3180
- 3185
- 3190
- 3195
- 3200
- 3205
- 3210
- 3215
- 3220
- 3225
- 3230
- 3235
- 3240
- 3245
- 3250
- 3255
- 3260
- 3265
- 3270
- 3275
- 3280
- 3285
- 3290
- 3295
- 3300
- 3305
- 3310
- 3315
- 3320
- 3325
- 3330
- 3335
- 3340
- 3345
- 3350
- 3355
- 3360
- 3365
- 3370
- 3375
- 3380
- 3385
- 3390
- 3395
- 3400
- 3405
- 3410
- 3415
- 3420
- 3425
- 3430
- 3435
- 3440
- 3445
- 3450
- 3455
- 3460
- 3465
- 3470
- 3475
- 3480
- 3485
- 3490
- 3495
- 3500
- 3505
- 3510
- 3515
- 3520
- 3525
- 3530
- 3535
- 3540
- 3545
- 3550
- 3555
- 3560
- 3565
- 3570
- 3575
- 3580
- 3585
- 3590
- 3595
- 3600
- 3605
- 3610
- 3615
- 3620
- 3625
- 3630
- 3635
- 3640
- 3645
- 3650
- 3655
- 3660
- 3665
- 3670
- 3675
- 3680
- 3685
- 3690
- 3695
- 3700
- 3705
- 3710
- 3715
- 3720
- 3725
- 3730
- 3735
- 3740
- 3745
- 3750
- 3755
- 3760
- 3765
- 3770
- 3775
- 3780
- 3785
- 3790
- 3795
- 3800
- 3805
- 3810
- 3815
- 3820
- 3825
- 3830
- 3835
- 3840
- 3845
- 3850
- 3855
- 3860
- 3865
- 3870
- 3875
- 3880
- 3885
- 3890
- 3895
- 3900
- 3905
- 3910
- 3915
- 3920
- 3925
- 3930
- 3935
- 3940
- 3945
- 3950
- 3955
- 3960
- 3965
- 3970
- 3975
- 3980
- 3985
- 3990
- 3995
- 4000
- 4005
- 4010
- 4015
- 4020
- 4025
- 4030
- 4035
- 4040
- 4045
- 4050
- 4055
- 4060
- 4065
- 4070
- 4075
- 4080
- 4085
- 4090
- 4095
- 4100
- 4105
- 4110
- 4115
- 4120
- 4125
- 4130
- 4135
- 4140
- 4145
- 4150
- 4155
- 4160
- 4165
- 4170
- 4175
- 4180
- 4185
- 4190
- 4195
- 4200
- 4205
- 4210
- 4215
- 4220
- 4225
- 4230
- 4235
- 4240
- 4245
- 4250
- 4255
- 4260
- 4265
- 4270
- 4275
- 4280
- 4285
- 4290
- 4295
- 4300
- 4305
- 4310
- 4315
- 4320
- 4325
- 4330
- 4335
- 4340
- 4345
- 4350
- 4355
- 4360
- 4365
- 4370
- 4375
- 4380
- 4385
- 4390
- 4395
- 4400
- 4405
- 4410
- 4415
- 4420
- 4425
- 4430
- 4435
- 4440
- 4445
- 4450
- 4455
- 4460
- 4465
- 4470
- 4475
- 4480
- 4485
- 4490
- 4495
- 4500
- 4505
- 4510
- 4515
- 4520
- 4525
- 4530
- 4535
- 4540
- 4545
- 4550
- 4555
- 4560
- 4565
- 4570
- 4575
- 4580
- 4585
- 4590
- 4595
- 4600
- 4605
- 4610
- 4615
- 4620
- 4625
- 4630
- 4635
- 4640
- 4645
- 4650
- 4655
- 4660
- 4665
- 4670
- 4675
- 4680
- 4685
- 4690
- 4695
- 4700
- 4705
- 4710
- 4715
- 4720
- 4725
- 4730
- 4735
- 4740
- 4745
- 4750
- 4755
- 4760
- 4765
- 4770
- 4775
- 4780
- 4785
- 4790
- 4795
- 4800
- 4805
- 4810
- 4815
- 4820
- 4825
- 4830
- 4835
- 4840
- 4845
- 4850
- 4855
- 4860
- 4865
- 4870
- 4875
- 4880
- 4885
- 4890
- 4895
- 4900
- 4905
- 4910
- 4915
- 4920
- 4925
- 4930
- 4935
- 4940
- 4945
- 4950
- 4955
- 4960
- 4965
- 4970
- 4975
- 4980
- 4985
- 4990
- 4995
- 5000
- 5005
- 5010
- 5015
- 5020
- 5025
- 5030
- 5035
- 5040
- 5045
- 5050
- 5055
- 5060
- 5065
- 5070
- 5075
- 5080
- 5085
- 5090
- 5095
- 5100
- 5105
- 5110
- 5115
- 5120
- 5125
- 5130
- 5135
- 5140
- 5145
- 5150
- 5155
- 5160
- 5165
- 5170
- 5175
- 5180
- 5185
- 5190
- 5195
- 5200
- 5205
- 5210
- 5215
- 5220
- 5225
- 5230
- 5235
- 5240
- 5245
- 5250
- 5255
- 5260
- 5265
- 5270
- 5275
- 5280
- 5285
- 5290
- 5295
- 5300
- 5305
- 5310
- 5315
- 5320
- 5325
- 5330
- 5335
- 5340
- 5345
- 5350
- 5355
- 5360
- 5365
- 5370
- 5375
- 5380
- 5385
- 5390
- 5395
- 5400
- 5405
- 5410
- 5415
- 5420
- 5425
- 5430
- 5435
- 5440
- 5445
- 5450
- 5455
- 5460
- 5465
- 5470
- 5475
- 5480
- 5485
- 5490
- 5495
- 5500
- 5505
- 5510
- 5515
- 5520
- 5525
- 5530
- 5535
- 5540
- 5545
- 5550
- 5555
- 5560
- 5565
- 5570
- 5575
- 5580
- 5585
- 5590
- 5595
- 5600
- 5605
- 5610
- 5615
- 5620
- 5625
- 5630
- 5635
- 5640
- 5645
- 5650
- 5655
- 5660
- 5665
- 5670
- 5675
- 5680
- 5685
- 5690
- 5695
- 5700
- 5705
- 5710
- 5715
- 5720
- 5725
- 5730
- 5735
- 5740
- 5745
- 5750
- 5755
- 5760
- 5765
- 5770
- 5775
- 5780
- 5785
- 5790
- 5795
- 5800
- 5805
- 5810
- 5815
- 5820
- 5825
- 5830
- 5835
- 5840
- 5845
- 5850
- 5855
- 5860
- 5865
- 5870
- 5875
- 5880
- 5885
- 5890
- 5895
- 5900
- 5905
- 5910
- 5915
- 5920
- 5925
- 5930
- 5935
- 5940
- 5945
- 5950
- 5955
- 5960
- 5965
- 5970
- 5975
- 5980
- 5985
- 5990
- 5995
- 6000
- 6005
- 6010
- 6015
- 6020
- 6025
- 6030
- 6035
- 6040
- 6045
- 6050
- 6055
- 6060
- 6065
- 6070
- 6075
- 6080
- 6085
- 6090
- 6095
- 6100
- 6105
- 6110
- 6115
- 6120
- 6125
- 6130
- 6135
- 6140
- 6145
- 6150
- 6155
- 6160
- 6165
- 6170
- 6175
- 6180

$R_1$  and  $R_2$  independently from each other have the meaning of H or lower alkyl,  
 $X$  has the meaning of imino, oxa or thia;  
 $Y$  has the meaning of hydrogen, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and  
 $Z$  has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherified or esterified hydroxy, nitro, cyano, carboxy, esterified carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if more than one rest  $Z$  is present ( $m \geq 2$ ), the substituents  $Z$  are equal or different from each other, and wherein the bonds marked with an arrow are single or double bonds; or an N-oxide of said compound, wherein one or more N-atoms carry an oxygene atom, or a salt thereof.

[0016] A preferred salt is the salt of an organic acid, especially a succinate.


[0017] These compounds can preferentially be used as compound I or II in the inventive pharmaceutical composition.

[0018] Compounds which stop a tyrosin phosphorylation, or the persistent angiogenesis, respectively, which results in a prevention of tumor growth and tumor spread, are for example anthranilic acid derivatives of general formula IV






in which


$A$  has the meaning of group  $=NR^2$ ,  
 $W$  has the meaning of oxygen, sulfur, two hydrogen atoms or the group  $=NR^8$ ,  
 $Z$  has the meaning of the group  $=NR^{10}$  or  $=N-$ ,  $-N(R^{10})-(CH_2)_q-$ , branched or unbranched  $C_{1-6}$ -Alkyl or is the group



or  $A$ ,  $Z$  and  $R^1$  together form the group



m, n and o has the meaning of 0 - 3,  
q has the meaning of 1 - 6,  
R<sub>a</sub>, R<sub>b</sub>, R<sub>c</sub>, R<sub>d</sub>, R<sub>e</sub>, R<sub>f</sub> independently from each other have the meaning of hydrogen, C<sub>1-4</sub> alkyl or the group =NR<sup>10</sup>,  
and/ or R<sub>a</sub> and/ or R<sub>b</sub> together with R<sub>c</sub> and or R<sub>d</sub> or R<sub>c</sub> together with R<sub>e</sub> and/ or R<sub>f</sub> form a  
bound, or up to two of the groups R<sub>a</sub>-R<sub>f</sub> form a bridge with each up to 3 C-atoms with R<sup>1</sup> or R<sup>2</sup>,  
X has the meaning of group =NR<sup>9</sup> or =N-,  
Y has the meaning of group -(CH<sub>2</sub>)<sub>p</sub>,  
P has the meaning of integer 1-4,  
R<sup>1</sup> has the meaning of unsubstituted or optionally substituted with one or more of halogene, C<sub>1-6</sub>-  
alkyl, or C<sub>1-6</sub>-alkyl or C<sub>1-6</sub>-alkoxy, which is optionally substituted by one or more of halogen,  
or is unsubstituted or substituted aryl or heteroaryl,  
R<sup>2</sup> has the meaning of hydrogen or C<sub>1-6</sub>-alkyl, or form a bridge with up to 3 ring atoms with R<sub>a</sub>-  
R<sub>f</sub> together with Z or R<sub>1</sub>,  
R<sup>3</sup> has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally  
substituted with one or more of für halogen, C<sub>1-6</sub>-alkyl, C<sub>1-6</sub>-alkoxy or hydroxy,  
R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> independently from each other have the meaning of hydrogen, halogen or C<sub>1-6</sub>-alkoxy, C<sub>1-6</sub>-  
alkyl or C<sub>1-6</sub>-carboxyalkyl, which are unsubstituted or optionally substituted with one or more  
of halogen, or R<sup>5</sup> and R<sup>6</sup> together form the group




R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup> independently from each other have the meaning of hydrogen or C<sub>1-6</sub>-alkyl, as well as their  
isomers and salts.

[0019] These compounds can also preferentially be used as compound I or II in the inventive pharmaceutical com-  
position.

[0020] More preferentially compounds of geneareal formula V

5

10




V,

15

in which


R¹ has the meaning of group

20



25


30



35

in which R⁵ is chloro, bromo or the group -OCH₃,

40




45

in which R⁷ is -CH₃ or chloro,

50

55






in which R<sup>8</sup> is -CH<sub>3</sub>, fluoro,  
chloro or -CF<sub>3</sub>

in which R<sup>4</sup> is fluoro,  
chloro, bromo, -CF<sub>3</sub>,  
-N=C, -CH<sub>3</sub>, -OCF<sub>3</sub> or  
-CH<sub>2</sub>OH

in which R<sup>6</sup> is  
-CH<sub>3</sub> or chloro

R<sup>2</sup> has the meaning of pyridyl or the group



and

R<sup>3</sup> has the meaning of hydrogen or fluoro, as well as their isomers and salts can be used as compound I or II in the inventive pharmaceutical composition.

[0021] These compounds have the same properties as already mentioned above under compound IV and can be used for the treatment of angiogeneous diseases. Compositions comprise compounds of general formulars I, IV and V, alone or in combination.

The above mentioned compounds are also claimed matter within the inventive combinations.

[0022] A further example for ligand binding inhibitors are peptides and DNA sequences coding for such peptides, which are used for the treatment of angiogeneous diseases. Such peptides and DNA sequences are disclosed in Seq. ID No. 1 to 59 of the sequence protocol. It has been shown that Seq. ID Nos. 34 and 34a are of main interest.

[0023] Claimed matter of the instant invention are therefor pharmaceutical compositions

a) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

b) comprising one or several agents as compound I which are targeted to the endothelium via of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

c) comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/ Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium,

d) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

e) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to

the endothelium via one or several of the Angiopoietin/Tie receptor systems,

f) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems,

g) comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems and

h) comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

**[0024]** For a sequential therapeutical application the inventive pharmaceutical compositions can be applied simultaneously or separately.

**[0025]** The inventive compositions comprise as compound I or as compound II at least one of

a) compounds which inhibit receptor tyrosine kinase activity,

b) compounds which inhibit ligand binding to receptors,

c) compounds which inhibit activation of intracellular signal pathways of the receptors,

d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,

e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,

f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

These compositions are also claimed matter of the present invention.

**[0026]** Also claimed matter of the present invention are pharmaceutical compositions which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59. Of most value are pharmaceutical compositions, which comprise as compound I and/ or II Seq. ID Nos. 34a und pharmaceutical compositions according to claims which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35 and/ or scFv-tTF conjugate.

**[0027]** Further preferred matter of the present invention are pharmaceutical compositions, which comprise as compound I and/ or II at least one small molecule of general formula I, general formula IV and/ or general formula V.

**[0028]** The most preferred compound which can be used as compound I or II in the inventive composition is (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate.

Therefore, claimed matter of the present invention are also pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35 and/ or scFv-tTF conjugate and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35 and/ or scFv-tTF conjugate, with the proviso that compound I is not identically to compound II, and most preferred pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35 and/ or scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35.

**[0029]** The small molecule compounds, proteins and DNA's expressing proteins, as mentioned above can be used as medicament alone, or in form of formulations for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis and damage of nerve tissues.

The treatment of the damaged nerve tissues with the inventive combination hinders the rapid formation of scars at the damaged position. Thus, there is no scar formation before the axons communicate with each other. Therefore a reconstruction of the nerve bindings is much more easier.

**[0030]** Further, the inventive combinations can be used for suppression of the ascites formation in patients. It is also possible to suppress VEGF oedemas.

For the use of the inventive combinations as medicament the compounds will be formulated as pharmaceutical composition. Said formulation comprises beside the active compound or compounds acceptable pharmaceutically, organ-

ically or inorganically inert carriers, such as water, gelatine, gum arabic, lactose, starch, magnesium stearate, talcum, plant oils, polyalkylene glycols, etc. Said pharmaceutical preparations can be applied in solid form, such as tablets, pills, suppositories, capsules, or can be applied in fluid form, such as solutions, suspensions or emulsions.

If necessary, the compositions additionally contain additives, such as preservatives, stabilizer, detergents or emulgators, salts for alteration of the osmotic pressure and/or buffer.

These uses are also claimed matter of the instant invention, as well as the formulations of the active compounds

**[0031]** For parenteral application especially injectable solutions or suspensions are suitable, especially hydrous solutions of the active compound in polyhydroxyethoxylated castor-oil are suitable.

As carrier also additives can be used, such as salts of the gallic acid or animal or plant phospholipids, as well as mixtures thereof, and liposomes or ingredients thereof.

For oral application especially suitable are tablets, pills or capsules with talcum and/or hydrocarbon carriers or binders, such as lactose, maize or potato starch.

**[0032]** The oral application can also be in form of a liquid, such as juice, which optionally contains a sweetener.

The dosis of the active compound differs depending on the application of the compound, age and weight of the patient, as well as the form and the progress of the disease.

The daily dosage of the active compound is 0,5-1000 mg, especially 50-200 mg. The dosis can be applied as single dose or as two or more daily dosis.

**[0033]** These formulations and application forms are also part of the instant invention.

**[0034]** Combined functional interference with VEGF/VEGF receptor systems and with Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to interference with one ligand/receptor system overlaps with the biological response to interference with a second ligand/receptor system. Alternatively, combined functional interference with VEGF/VEGF receptor systems or with Angiopoietin/Tie receptor systems and targeting of cytotoxic agents via VEGF/VEGF receptor systems or via Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to functional interference with a ligand/receptor system overlaps in time with targeting of cytotoxic agents.

**[0035]** The invention is also directed to a substance which functional interferes with both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems, or which are targeted via both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems.

**[0036]** VEGF/VEGF receptor systems include the ligands VEGF-A, VEGF-B, VEGF-C, VEGF-D, PlGF, and the receptor tyrosine kinases VEGF-R1 (Flt1), VEGF-R2 (KDR/Flk1), VEGF-R3 (Flt4), and their co-receptors (i.e. neuropilin-1). Angiopoietin/Tie receptor systems include Ang1, Ang2, Ang3/Ang4, and angiopoietin related polypeptides which bind to Tie1 or to Tie2, and the receptor tyrosine kinases Tie1 and Tie2.

**[0037]** Pharmaceutical compositions of the present invention can be used for medicinal purposes. Such diseases are, for example, cancer, cancer metastasis, angiogenesis including retinopathy and psoriasis. Pharmaceutical compositions of the present invention can be applied orally, parenterally, or via gene therapeutic methods.

**[0038]** Therefor the present invention also concerns the use of pharmaceutical compositions for the production of a medicament for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

**[0039]** The following example demonstrates the feasibility of the disclosed invention, without restricting the invention to the disclosed example.

#### Example 1

**[0040]** Superior effect on inhibition of tumor growth via combination of inhibition of the VEGF A/VEGF receptor system together with functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention was demonstrated in an A375v human melanoma xenograft model.

**[0041]** Human melanoma cell line A375v was stably transfected to overexpress the extracellular ligand-neutralizing domain of human Tie2 receptor tyrosine kinase (sTie2; compound II) (Siemeister et al., Cancer Res. 59, 3185-3191, 1999). For control, A375v cells were stably transfected with the empty expression vector (A375v/pCEP). Swiss nu/nu mice were s.c. injected with  $1 \times 10^6$  transfected A375v/sTie2 or A375v/pCEP tumor cells, respectively. Animals receiving compound I were treated for up to 38 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Various modes of treatment are described in Table 1. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 1

5	treatment group	mode of treatment	
		(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	sTie2 (compound II)
	Group 1: A375v/pCEP	-	-
10	Group 2: A375v/pCEP	+	-
	Group 3: A375v/sTie2	-	+
15	Group 4: A375v/sTie2	+	+

[0042] Tumors derived from A375v/pCEP control cells reached a size of approx. 250 mm<sup>2</sup> (mean area) within 24 days (Figure 1) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) or separate interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) delayed growth of tumors to a size of approx. 250 mm<sup>2</sup> to 31 days, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of interference with the VEGF/VEGF receptor system by means of the kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I + compound II, treatment group 4) delayed growth of the tumors to a size of approx. 250 mm<sup>2</sup> to 38 days. This result clearly demonstrates the superior effect of a combination of interference with the VEGF-A/VEGF receptor system and the Angiopoietin/Tie2 receptor system over separate modes of intervention.

#### Description of the figures

[0043] Fig. 1 shows the superior effect of combination of interference with VEGF/VEGF receptor system by means of an specific tyrosine kinase inhibitor and with the Angiopoietin/Tie2 receptor system by means of a soluble receptor domain on inhibition of tumor growth (treatment modes of groups 1-4 are given in Table 1). The abbreviations have the following meaning:

mock, con. = treatment group 1  
 mock+VEGF-A = treatment group 2  
 sTIE2-c113 = treatment group 3  
 sTIE2-c113+VEGF-A = treatment group 4

## Sequenzprotokoll

5 <110> Schering Aktiengesellschaft  
 <120> Combinations and compositions which interfere with VEGF/ VEGF and  
 angiopoietin/ Tie receptor function and their use  
 <130> 51849AEP M1XX00-P  
 10 <140>  
 <141>  
 <160> 59  
 15 <210> 1  
 <211> 1835  
 <212> DNA  
 <213> Human  
 <400> 1  
 20  
 ttttacagtt ttccttttct tcagagtta ttttgaattt tcatttttgg ataaccaagc 60  
 agctctttta gaagaatgca cagaagagtc attctggcac ttttggatag tacataagat 120  
 tttctttttt ttttttaaat tttttttaat agtcacattc agctcgcttg ctcaaaccag 180  
 actcccacat tgggtgagca agatgagccc ataggattcc agagttaata cgtaaccgta 240  
 25 tatacaaaca gccaaaaaac cataatgggt ccacagggat ggagcaggga agggcatctc 300  
 taacgtgtcc tctagtctat ctctcgctaaa cagaaccac gttacacatg ataactagag 360  
 agcacactgt gttgaaacga ggatgctgac cccaaatggc acttggcagc atgcagttta 420  
 aagcaaaaga gacatccttt aataactgta taaaatccag gcagttccat taaaggggtt 480  
 aagaaaacca acaacaacaa aaagcgaggg actgtctgtt gtcactgtca aaaaggcact 540  
 tggagttaat gggaccagga ttggaggact cttagctgat acagatttca gtacgatttc 600  
 attaaaaggc ttggatgtta agagaggaca ctacgaggtt cctgaaggga gacgctgaga 660  
 30 tggaccgctg agaagcggaa cagatgaaca caaagggaatc aaatctttac aaccaaattg 720  
 catttaagcg acaacaaaaa aaggcaaac ccacaaacgca acctaaccac agcaaatct 780  
 aagcaaaatc agacaacgaa gcagcgatgc atagctttcc tttgagagaa cgcatacctt 840  
 gagacgctac gtgccaacct aagttctcaa cgacagcttc acagtaggat tattgtgata 900  
 aaaatgactc aagcgatgca aaaagtttca tctgttccca gaatccgagg gagaactgag 960  
 35 gtgatcgtta gagcatagcg acatcacgtg cggtttctta atgtccctgg tggcggatag 1020  
 gccgagtcct cggaaggaca tctggacacc actttcagcc acctccttg acggggcgaca 1080  
 tccgccaaag tcatccttta tcccgagtaa taactttaat tcttttctaa catttacacg 1140  
 gcaaacagga atgcagtaaa cgtccacgtc cgtcccacgg ctgggctgccc gttccgtttc 1200  
 ctccacgaac gggtagcgcg tccatgaga aaggatattt ggcaatttta tattccacag 1260  
 tcaggtgggt ctgcgtagc tcatttaatg ttaaacgccca tcaggggcct ctccctccgt 1320  
 40 ttctgccagg ggttttctt gtcttctcct tggcgagctc gtgggcagat cttctctggt 1380  
 gggggctggc tgctggctcc gagggggcat ccgagtcctg tctgtctgct tctcctgca 1440  
 ggctgggcag ctggccacca ctctctccgac tgcacccctc caacaagcat cgcagggcac 1500  
 tgtcctcggg ggtacagacc gtggtcccac attcgctacc actctgttcc acgtcatcca 1560  
 ggtacacgag ctgcgtgtag gccgtgctgt ctggggctcg aggtctcttc tgcgtgtgct 1620  
 cttggacggg cgggtagttc tgctgcagag acaaagcatc tccccttccc ttccgggctg 1680  
 45 attttggttc attcatatct acgccagagt ccaaactggc atcattactt ccgttccttc 1740  
 cagctctttg gagaatcaat gtatgaatgt caacctgac cgttggaact gccatccaag 1800  
 gagacgaacc acgcccgggg gtgcggaagc ggcct  
 <210> 2  
 50 <211> 581  
 <212> DNA  
 <213> Human  
 <400> 2  
 55 gttctagatt gttttattca gtaattagct cttaagaccc ctggggcctg tgctaccag 60  
 acactaaca cagtctctat ccagttgctg gttctgggtg acgtgatctc ccatcatga 120

EP 1 166 798 A1

tcaacttact tctgtggtcc cattagggaa gtggtgacct cgggagctat ttgcctgttg 180  
 agtgcacaca cctggaaaca tactgtctctc attttttcat ccacatcagt gagaaatgag 240  
 tggcccgtta gcaagatata actatgcaat catgcaacaa agctgcctaa taacatttca 300  
 5 tttattacag gactaaaagt tcattattgt ttgtaaaagg tgaattcata acctctgcag 360  
 agttatagtt catacacagt tgatttccat ttataaaggc agaaagtcc tgttttctct 420  
 aaatgtcaag ctttgactga aaactcccgt ttttccagtc actggagtgt gtgcgtatga 480  
 aagaaaatct ttagcaatta gatgggagag aagggaata gtacttgaaa tgtaggccct 540  
 cacctcccca tgacatctc catgagcctc ctgatgtagt g  
  
 <210> 3  
 <211> 516  
 <212> DNA  
 <213> Human  
  
 <400> 3  
 15 tagagatgtt ggttgatgac ccccggtatc tggagcagat gaatgaagag tctctggaag 60  
 tcagcccaga catgtgcatc tacatcacag aggacatgct catgtcgcgg aacctgaatg 120  
 gacactctgg gttgattgtg aaagaaattg ggtcttccac ctcgagctct tcagaaacag 180  
 ttgttaagct tctgggccag agtactgatt ctcttccaca gactatatgt cggaaccaa 240  
 agacctccac tgatcgacac agcttgagcc tcgatgacat cagactttac cagaaagact 300  
 20 tcttgcgcag tgcaggtctg tgtcaggaca ctgctcagag ttacacctt ggatgtggcc 360  
 atgaactgga tgaggaaggc ctctattgca acagtgtctt ggcccagcag tgcataca 420  
 tccaagatgc ttttccagtc aaaagaacca gcaataactt ttctctggat ctactcatg 480  
 atgaagttcc agagtgtgtt gtgtaaaagtc cgtctg  
  
 <210> 4  
 <211> 1099  
 <212> DNA  
 <213> Human  
  
 <400> 4  
 30 cccacaacac aggggcccgt aaacacgcca gcctctcctc tgtggtcagc ttggcccagt 60  
 cctgtcact ggatcacagc ccattgtagg tggggcatgg tggggatcag ggcccctggc 120  
 ccacggggag gtagaagaag acctgggtccg tgtaagggtc tgagaagggt ccctgggtcg 180  
 ggggtgcgtc ttggcccttg cgtgcccctc tccccgggtc gaggcagcga cacagcaggt 240  
 gcaccaactc cagcaggtta agcaccaggg agatgagtcc aaccaccaac atgaagatga 300  
 tgaagatggt ctctcctggt gggcgagaga caaagcagtc cacgaggtag gggcaggggt 360  
 35 ctgctgggca cacaacacg ggctccatgg tccagccgta caggcgccac tggccataga 420  
 ggaagccctg ctctagcaca ctcttgca gaacactggc gacatagggt cccatcagtg 480  
 ctccgcggat gcgcaggcga ccattctctg ccaccgagat cttggccatc tgacgtctta 540  
 cgcccgccag cgcccgctcc acctgtgggt ccttggccgg cagtgcgccg agctccccct 600  
 ccttctgcgg cagccgctct tctcgccgag acaggtaat gacatggccc aggtagacca 660  
 ggggtgggtgt gctgacgaag aggaactgca gcaccagta gcggtgtgg gagatgggga 720  
 40 aggcctgggtc atagcagacg ttggtgcagc ctgggtgggc cgtgttacac tcgaaatctg 780  
 actgctcgtc accccacact gactcgccgg ccaggcccag gatgaggatg cggaagatga 840  
 agagcaccgt cagccagatc ttaccaccca cggtcgagtg ctctggacc tggccagca 900  
 acttctccac gaagccccag tcacccatgg ctcccgggct tccgtcggca aggagacaga 960  
 gcacgtcagt gtgtcagcat ggcacccctc tgggtcggcc agcaacaagc ctgcaggag 1020  
 45 gtctgccacg cccgttctac cgctcgctg cgggcgggc cagggtgagg tggggacgat 1080  
 ggccggagtg acgcccgcg  
  
 <210> 5  
 <211> 1015  
 <212> DNA  
 <213> Human  
  
 <400> 5  
 55 gaggataggg agcctgggggt caggagtgtg ggagacacag cgagactctg tctccaaaaa 60  
 aaaaagtgtc ttttgaataat gttgaggttg aaatgatggg aaccaacatt ctttgattt 120  
 agtggggagc ataatagcaa acacccctt ggttcgcaca tgtacaggaa tgggaccag 180  
 ttggggcaca gccatggact tccccgccct ggaatgtgtg gtgcaaagtg gggccaggc 240  
 ccagacccaa gaggagaggg tgggtccgag acaccccggt atgtcagcat ccccgacct 300  
 gccttctggc ggcacctccc ggggtgctgt ttgagtcagc aggcattggg tgagagcctg 360

EP 1 166 798 A1

5 gatatatgctg ggaacagggt gcagggggcca agcgttcctc cttcagcctt gacttggggcc 420  
 atgcaccccc tctcccccaa acacaaacaa gcacttctcc agtatgggtg caggacaggt 480  
 gtcccttcag tctcttggtt atgacctcaa gtccctactg ggccctgcag cccagcctgt 540  
 gttgtaacct ctgcgtcctc aagaccacac ctggaagatt cttcttcctt ttgaaggaga 600  
 atcatcattg ttgctttatc acttctaaga cattttgtac ggcacggaca agttaaacag 660  
 aatgtgcttc cctccctggg gtctcacacg ctcccacgag aatgccacag gggccgtgca 720  
 ctgggcaggc ttctctgtag aaccccaggg gcttcggccc agaccacagc gtcttgccct 780  
 gagcctagag cagggagtc cgaacttctg cattcacaga ccacctccac aattgtttata 840  
 10 accaaaaggcc tctgttctg ttatttcaact taaatcaaca tgctattttg ttttcaactca 900  
 cttctgactt tagcctcgtg ctgagccgtg tatccatgca gtcattgttca cgtgctagt 960  
 acgtttttct tcttacacat gaaaataaat gcataagtgt tagaagaaaa aaaaa  
  
 <210> 6  
 <211> 2313  
 <212> DNA  
 15 <213> Human  
  
 <400> 6  
  
 20 ccagagcagg cctgggtggtg agcaggggacg gtgcaccgga cggcgggatc gagcaaatgg 60  
 gtctggccat ggagcacgga gggctcctacg ctcgggcggg gggcagctct cggggctgct 120  
 ggtattacct gcgctacttc ttctctcttcg tctccctcat ccaattcctc atcatcctgg 180  
 ggctcgtgct cttcatggtc tatggcaacg tgcacgtgag cacagagtc aacctgcagg 240  
 ccaccgagcg ccgagccgag ggctatataca gtcagctcct agggctcacg gcctcccagt 300  
 ccaacttgac caaggagctc aacttcacca cccgcgcca ggtgacctc atgcagatgt 360  
 ggctgaatgc tcgcccgcac ctggaccgca tcaatgccag cttccgcccag tgcagggtg 420  
 accgggtcat ctacacgaac aatcagaggt acatggctgc catcatcttg agtgagaagc 480  
 25 aatgcagaga tcaattcaag gacatgaaca agagctgcga tgccttgctc ttcatgctga 540  
 atcagaaggt gaagacgctg gagtgaggaga tagccaagga gaagaccatt tgcactaagg 600  
 ataagaaaag cgtgctgctg aacaaacgcg tggcgaggga acagctgggt gaatgctga 660  
 aaaccgggga gctgcagcac caagagcgcc actggccaag gagcaactgc aaaaggtgca 720  
 agccctctgc ctgcccctgg acaaggacaa gtttgagatg gaccttcgta acctgtggag 780  
 ggactccatt atcccacgca gcctggacaa cctgggttac aacctctacc atcccctggg 840  
 30 ctcggaattg gcctccatcc gcagagcctg cgaccacatg cccagcctca tgagctccaa 900  
 ggtgaggag ctggcccggga gcctccgggc ggatategaa cgcgtggccc gcgagaactc 960  
 agacctccaa cgccagaagc tggaaagcca gcagggcctg cggggccagtc agggaggcga 1020  
 acagaaggtg gagaagaggg ctacggcccg ggaggccaag ctccaagctg aatgctccg 1080  
 gcagaccag ctagcgctgg aggagaaggc ggtgctgctg aaggaacgag acaacctggc 1140  
 caaggagctg gaagagaaga agagggaggg ggagcagctc aggatggagc tggccatcag 1200  
 35 aaactcagcc ctggacacct gcatcaagac caagtccgag ccgatgatgc cagtgtcaag 1260  
 gcccatgggc cctgtcccca acccccagcc catcgaccca gctagcctgg aggagttcaa 1320  
 gaggaagatc ctggagctcc agaggccccc tgcaggcatc cctgtagccc catccagtgg 1380  
 ctgaggaggg tccaggcctg aggaccaagg gatggcccga ctcgcggtt tgcggaggat 1440  
 gcagggatat gctcacagcg cccgacacaa cccctcccg ccgcccccaa ccaccaggg 1500  
 ccaccatcag acaactccct gcatgcaaac ccctagtacc ctctcacacc cgcaccccg 1560  
 40 cctcacgac cctcaccag agcacacggc cgcgagatg acgtcacgca agcaacggcg 1620  
 ctgacgtcac atatcaccgt ggtgatggcg tcacgtggcc atgtagacgt cacgaagaga 1680  
 tatagcgatg gcgtcgtgca gatgcagcac gtcgcacaca gacatgggga acttggcatg 1740  
 acgtcacacc gagatgcagc aacgacgtca cgggccatgt cgacgtcaca catattaatg 1800  
 tcacacagac gcggcgatgg catcacacag acggtgatga tgtcacacac agacacagt 1860  
 acaacacaca ccatgacaac gacacctata gatatggcac caacatcaca tgcacgcatg 1920  
 45 cctttcaca cacactttct acccaattct cacctagtgt caggttcccc cgacctggc 1980  
 acacgggcca aggtaccac aggatcccat cccctcccgc acagccctgg gcccagcac 2040  
 ctcccctcct ccagcttctt ggctcccag ccacttcctc acccccagtg cctggacccg 2100  
 gaggtgagaa caggaagcca ttacacctcg ctccttgagc gtgagtgtt ccaggacccc 2160  
 ctcgggggccc tgagccgggg gtgaggggtca cctgtgtcgg ggaggggagc cactccttct 2220  
 50 cccccaactc ccagccctgc ctgtggcccg ttgaaatgtt ggtggcactt aataaatatt 2280  
 agtaaactct taaaaaaaaa aaaaaaaaaa aaa  
  
 <210> 7  
 <211> 389  
 <212> DNA  
 55 <213> Human  
  
 <400> 7

EP 1 166 798 A1

5 gccaaaaaga tggcttcaaa agtaagaatg aaacatttga tccattcagc tttaggctat 60  
 gccactggat tcatgtctag aaaagatagg ataatttctg taaagaaatg aagaccttgc 120  
 tattctaaaa tcagatcctt acagatccag atttcaggaa acaaatacat aggggactaa 180  
 ctttccttgt tcagattagt ttttctcctt tgcacccagc tatataatat gaggaagtaa 240  
 tgacttttta aaagtgtttt agttttccat ttctttgata tgaaaagtaa tatttcggga 300  
 gaaccctgag ctattaataa tctatgtggc tagtgcgat atattggtct gaatttggtc 360  
 tccttttgtg gtgtccagtg ggtaacatc  
  
 <210> 8  
 <211> 157  
 <212> DNA  
 <213> Human  
  
 <400> 8  
  
 15 tgctttaaac agctgtgtca aaaactgaca tcagagagta aattgaattt ggttttgtag 60  
 gaagcaggaa gcaagcccac tcaaactgtga aatttggcat gagggatcca gtaactttct 120  
 cctcaatctg tgaactatat gtgagtttga tattttg  
  
 <210> 9  
 <211> 561  
 <212> DNA  
 <213> Human  
  
 <400> 9  
  
 25 aatagtcaaa acataaacia aagctaatta actggcactg ttgtccactg agactaagtg 60  
 gatgttgtg gctgacatac aggtcagcc agcagagaaa gaattctgaa tttcccttgc 120  
 tgaactgaac tattctgtta catatggttg acaaactctgt gtgttatttc ttttctacct 180  
 accatattta aatttatgag tatcaaccga ggacatagtc aaaccttcga tgatgaacat 240  
 tcctgatttt ttgcctgatt aatctctgtt gagctctact tgtggtcatt caagatttta 300  
 tgatgttgaa aggaaaagtg aatatgacct ttaaaaattg tattttgggt gatgatagtc 360  
 tcaccactat aaaactgtca attattgcct aatgttaaag atatccatca ttgtgattaa 420  
 30 ttaaacctat aatgagtatt cttaatggag aattcttaat ggatggatta tcccctgata 480  
 ttttctttaa aatttctctg cacacacagg acttctcatt ttccaataaa tgggtgtact 540  
 ctgccccaat ttctaggaaa a  
  
 <210> 10  
 <211> 1508  
 <212> DNA  
 <213> Human  
  
 <400> 10  
  
 40 cacaaacacg agagactcca cggctctgct gagcaccgcc agcctcctag gctccagcac 60  
 tcgcaggccc attcttctgc acgagcctct ctgtccagat ccataagcac ggtagctca 120  
 gggctcgcga gcagtacgag gacaagtacc agcagcagct cctctgaaca gagactgcta 180  
 ggatcatcct tctcctccgg gcctgttgct gatggcataa tccgggtgca acccaaatct 240  
 gagctcaagc caggtgagct taagccactg agcaaggaa atttggcct gcacgcctac 300  
 aggtgtgagg actgtggcaa gtgcaaatgt aaggagtga cctaccaag gcctctgcca 360  
 tcagactgga tctgcgacaa gcagtgcctt tgctcggccc agaactgat tgactatggg 420  
 45 acttgtgtat gctgtgtgaa aggtctcttc tatcactgtt ctaatgatga tgaggacaag 480  
 tgtgctgaca acccatgttc ttgcagccag tctcactgtt gtacacgatg gtcagccatg 540  
 ggtgtcatgt ccctcttttt gccttgttta tgggtgtacc ttccagccaa ggggtgcctt 600  
 aaattgtgcc aggggtgtta tgaccgggtt aacaggcctg gttgccgctg taaaaactca 660  
 aacacagttt gctgcaaagt tcccactgtc ccccctagga actttgaaaa accaacaatg 720  
 catcattaat caggaatatt acagtaatga ggattttttc tttctttttt taatacacat 780  
 atgcaaccaa ctaaacagtt ataactttgg cactgttaat agaaagtgg gatagctctt 840  
 50 gctgtttgag gtgaaatgct ttttgtccat gtgccgtttt aactgatag cttgttagaa 900  
 ctcagctaat ggagctcaaa gtatgagata cagaacttgg tgacctatgt attgcataag 960  
 ctaaagcaac acagacactc ctaggcaaa tttttgtttg tgaatagtac ttgcaaaact 1020  
 tgtaaattag cagatgactt ttttccattg ttttctccag agagaatgtg ctatattttt 1080  
 gtatatacaa taatatttgc aactgtgaaa aacaagtgg gccatactac atggcacaga 1140  
 55 cacaaaaat tttactaata tgtgtacat tcggaagaat gtgaatcaat cagtatgttt 1200  
 ttagattgta ttttgcctta cagaaagcct ttattgtaag actctgattt ccctttggac 1260  
 ttcattgtata ttgtacagtt acagtaaaat tcaaccttta ttttctaatt ttttcaacat 1320



# EP 1 166 798 A1

attgttttagt gtaaagaata tttatttgaa gttttattat tttataaaaa agaataattta 1380  
 ttttaagagg catcttacaa attttgcccc ttttatgagg atgtgatagt tgctgcaaat 1440  
 gaggggttac agatgcatat gtccaatata aaatagaaaa tatattaacg tttgaaatta 1500  
 5 aaaaaaaa  
 <210> 11  
 <211> 389  
 <212> DNA  
 <213> Human  
 10  
 <400> 11  
 gggcaggtga tcagggcaca catttcccgt ccattgagac agtagcattc ccggcaccca 60  
 tcgtgccagc tctcctcatt tttatgatga tgaccatcca cggtgagaca agtgcccagc 120  
 aggatgggtg gccagctga agcacaggcc gctctgcact tgcagataag acagccgtga 180  
 15 ctgtcctgct ggaaacccaa ggggcagatc ttactgcatg agagctctgg acatttctta 240  
 cagcgacaga tgtcacagcc gtgcttattc ttcagcaatc caagtggaca atacttgtca 300  
 cagatttatgg gtctgcactt cttgggcctt gggcggcact cacagatctc acagttttgg 360  
 acctcggccg cgaccacgct ggggtaccga  
 <210> 12  
 20 <211> 981  
 <212> DNA  
 <213> Human  
 <400> 12  
 25 tttttttttt ttggattgca aaaatttatt aaaattggag acaactgtttt aatcttcttg 60  
 tgccatgaga ctccatcagg cagtctacaa agaccactgg gaggtgagg atcacttgag 120  
 ccagaagtt tgaggctgta gtaagcttca aaggccactg cactctagct tgggtgaggc 180  
 aagacccttt caagcagtaa gctgcatgct tgcttgttgt ggtcattaaa aaccctagtt 240  
 taggataaca acatattaat cagggcaaaa tacaaatgtg tgatgcttgt tagtagagta 300  
 acctcagaat caaaatggaa cgggtttaca gtgatcat tatatttcat ttggcagaat 360  
 30 cattacatca ttggttacac tgaaaatcat cacatgtacc aaaagctgac tcacctagtt 420  
 taggataaca ggtctgcctg tttgaagatg aaaaataata cccattttaa atttgcccta 480  
 ctcaatttcc ttctcagtca cattttaact tttaaacagc taatcactcc catctacaga 540  
 ttaagggtga tatgccacca aaaccttttg ccacctttaa aatttccttc aaagttttaa 600  
 ctaatgcctg catttcttca atcatgaatt ctgagtcctt tgcttcttta aaacttgctc 660  
 cacacagtgt agtcaagccg actctccata cccaagcaag tcatccatgg ataaaaacgt 720  
 35 taccaggagc agaaccatta agctggtcca ggcaagtgg actccaccat ttcaacttcc 780  
 agcttttctgt ctaatgcctg tgtgccaatg gcttgagtta ggcttgctct ttaggacttc 840  
 agtagctatt ctcatccttc cttggggaca caactgtcca taagggtcta tccagagcca 900  
 cactgcatct gcacccagca ccatacctca caggagtcca ctcccacgag ccgcctgtat 960  
 ataagagttc ttttgatgac g  
 40 <210> 13  
 <211> 401  
 <212> DNA  
 <213> Human  
 <400> 13  
 45 ataactacag cttcagcaga caactaaaga gactgcatta aggtgatttc tctggctata 60  
 aagagagccc ggccgcagag catgtgactg ctgggacctc tgggataggc aacactgccc 120  
 tctctccccc agagcgaccc cccgggcagg tccggggcca aggaatgacc cagcaactgc 180  
 tccctaccca gcacactctc tttactgcca cctgcaatta tgctgtgaag atgactgggt 240  
 gtgggtcatca cgattcagag aaatcaagat ctatgaccat tttaggcaaa gagagaaact 300  
 50 tggagaattg ctgaggacta ctgaaccttg ttttgctttt ttaaaaaata ctaaactctc 360  
 acttcagcat atttagttgt cattaaaaatt aagctgatat t  
 <210> 14  
 <211> 1002  
 <212> DNA  
 <213> Human  
 55 <400> 14

# EP 1 166 798 A1

5 gacaatataa aaagtggaaa caagcataaa ttgcagacat aaaataatct tctggtagaa 60  
 acagttgttg agaacagggt gagtagagca acaacaacaa aagcttatgc agtcaccttc 120  
 tttgaaatg ttaaatacaa gtccatttct ctttgtccag ctgggttttag cttagggtag 180  
 ccaattactt ctcttaaggt ccatggcatt cgccaggatt ctataaaagc caagttaact 240  
 gaagtaaata tctggggccc atcgcacccc cactaagtac tttgtcacca tgtgtatct 300  
 taaaagtcatt ttttcaactgt ttgactcaga atttgggact tcagagtcaa acttcattgc 360  
 ttactccaaa cccagtttaa ttccccactt ttttaagtag gcttagcttt gagtgtattt 420  
 tggctataac cgaaatgtaa atccaccttc aaacaacaaa gtttgacaag actgaaatgt 480  
 tactgaaaac aatggtgcca tatgctccaa agacatttcc ccaagataac tgccaaagag 540  
 10 tttttgagga ggacaatgat cattttatct gtaggagcct tgatatctct gcaaaataga 600  
 attaatagag ctcaaatgga gtagtaacca agcttttctg cccaggaagt aacaacatc 660  
 actacgaaca tgagagtaca agaggaaact ttcataatgc attttttcat tcatacattc 720  
 attcaataaa cattagccaa gctaattgtc caagccactg tgccaggtat taacaatata 780  
 acaacaataa aagacacagt ccttcctctc aagggtgtca gtctagtagg gaagatgatt 840  
 attcattaaa atttttggtg catcagaatc atgaggagct tgtcaaaaat gtaaatcct 900  
 15 gcctatgttc tcagatatcc tgggttaggtc aggagtgagg acccaaatc aattctttta 960  
 acaaacacta aagtgatgc taacacaggc ggtgtgagga cc

<210> 15  
 <211> 280  
 <212> DNA  
 20 <213> Human

<400> 15

25 cgaggtgggc caccctgtgc tggctcgaga tttttaaatg aggattacat taccctattt 60  
 ataattattcc tattctaate tattgtattc ttacaattaa atgtatcaaa taattcttaa 120  
 aaacattatt agaacaacac tgcctaatac cttataagac taaaaaaatc accaagatga 180  
 aactgtatta tgactctcaa tattttaaaca ttttaaaaaa tgttagtggt tgtaagcac 240  
 caatcttaac tatttcaccc gcccgggcgg ccgctcgagg

<210> 16  
 <211> 2041  
 30 <212> DNA  
 <213> Human

<400> 16

35 cccccgcag aactcccccc tgggaatagga tttttaaaac ccttgacaat tagaaatcct 60  
 atagagggtta gcatttttta ggtaaaaaata tgggtgcccc tacagggatc atgcaacttc 120  
 cttaaaacca attcagcaca tatgtataaa gaaccctttt taaaaacatt tgtacttgaa 180  
 atacagacac agtgatgctg aagacactaa acaaaaactg aaaagtacta taccttgata 240  
 aattttgtta ttgccttctt tagagacttt ataactctta gttgattttc aaggacttga 300  
 atttaataat ggggtaatta cacaagacgt aaaggatttt taaaaacaa gtattttttt 360  
 ttacctctag catcaattct tttataaaga atgctaataa aattacattt tttgttcagt 420  
 40 aaaaactgaag atagaccatt taaatgcttc taccaaattt aacgcagctt aattagggac 480  
 cagggtacata ttttcttctg aacatttttg gtcaagcatg tctaaccata aaagcaaatg 540  
 gaattttaag aggtagattt tttttccatg atgcattttg ttaataaatg tgtcaagaaa 600  
 ataaaaacaa gcaactgagtg tgttctcttg aagtataagg gtctaataaa aaataaaaaga 660  
 tagatatttg ttatagctctg acatttttaac agtcatagta ttagacgttt cgtgaccagt 720  
 gcatttttga ctctctcagg atcaaaaatac gagtctgcca actgtattaa atcctcctcc 780  
 45 accccctcca ccagttggtc cacagcttcc tgggtgggtcg ttgtcatcaa atccattggg 840  
 ccgaaatgaa catgaagcag atgcagcttg gagggcccg gctcgagcat tcaactcttg 900  
 ttctgtgaaa tatagtttat tgtcttttgt tatagcatcc ataagttctt tctgtagagg 960  
 tgggtctcca tttatccaga gtccactggg tgggttatta ccacttaaac cattagtagt 1020  
 atgctgtttt ttatacaaaa gcacataagc tgtgtccttt ggaaacctgc tcgtaatttt 1080  
 ctggactgac tgaatgaag taaatgtcac tctactgtca ttaataaaaa acccattctt 1140  
 50 ttgacatttc cttattttcc aaatcctgtt caaaaactgc actgggacta tctctcccta 1200  
 gtaaatgact ctgggaggat gctaattgcca gagcctcaga ctgggtgtgac atctgatatg 1260  
 aagagtctgt acttgtgata tttctggcat aagaatagta atgcccactt tcagaggata 1320  
 taccagagtg aaccacaacg gaacttaata gatagggcac caattttgtg cagggaagctt 1380  
 catcagtcct tgaaggcttt aatttttttag caaggttctc actaagatca gtgaagtcaa 1440  
 catctacaga ccaactttct gacaatgaag agaaagaagt aattcttcta actggcaact 1500  
 55 ccaaaaccag tggccagtga tacattgtct aaaattttcc ttctcacatg atacttctga 1560  
 tcatatgaaa atctcaggag agtaagaata aggtattcag gttcctccgt gatttgcata 1620

EP 1 166 798 A1

gttttctcag ctttttgag agaggcacag ttttcacaat aatattgggt atcaccagta 1680  
 agaatctctg gagcccaaaa aataatttag taagtcagtt actgaagggt tggtttcacc 1740  
 tcccgggttc tgaggtagat ctttattaac aagaatcttg ttagattcgt tagggacaga 1800  
 5 agtgttttca gaacagtaaa actcattagg aggactgcct atgggttttt cattcacaag 1860  
 tgagtcacag atgaaggcag ctgttggttg attataaaact actggctctt ctgaaggacc 1920  
 gggtagacag gcttgcatga gaccaccatc ttgtatactg ggtgatgatg ctggatcttg 1980  
 gacagacatg ttttccaaag aagaggaagc acaaaacgca agcgaaagat ctgtaaaggc 2040  
 t

<210> 17  
 <211> 235  
 <212> DNA  
 <213> Human

<400> 17

15 cgccccgggc aggtgtcagg ggttccaaac cagcctgggg aaacacagcg tagacccttc 60  
 acctctacaa ataaaaaatt aaaaaattag ccagggtgtg cagcgaacaa ctgtagtctc 120  
 agatactcag gagactgagc tggaaaggat cacttgagcc caagaagttc aaggttacag 180  
 tgggccacga tcatgtcatt acactccagc ttgggtgaca aaatgagact gtcta

<210> 18  
 <211> 2732  
 <212> DNA  
 <213> Human

<400> 18

25 gtgtggagtt tcagctgcta ttgactataa gagctatgga acagaaaaag cttgctggct 60  
 tcatgttgat aactacttta tatggagctt cattggacct gttaccttca ttattctgct 120  
 aaatattatc ttcttggtga tcacattgtg caaaatgttg aagcattcaa acactttgaa 180  
 accagatttc agcaggttgg aaaacattaa gtcttgggtg cttggcgctt tcgctcttct 240  
 gtgtcttctt ggccctcacct ggtccttttg gttgcttttt attaatgagg agactattgt 300  
 gatggcatat ctcttcacta tatttaatgc ttccaggga gtgttcattt tcatctttca 360  
 30 ctgtgctctc caaaagaaag tacgaaaaga atatggcaag tgcttcagac actcactactg 420  
 ctgtggaggc ctcccaactg agagtcccca cagttcagtg aaggcatcaa ccaccagaac 480  
 cagtgtctgc tattcctctg gcacacagag tcgtataaga agaattgtga atgatactgt 540  
 gagaaaacaa tcagaatctt cttttatctc aggtgacatc aatagcactt caacacttaa 600  
 tcaagggtggc ataaatctta atatattatt acaggactga catcacatgg tctgagagcc 660  
 catcttcaag atttatatca tttagaggac attcactgaa caatgccagg gatacaagtg 720  
 35 ccatggatac tctaccgcta aatggtaatt ttaacaacag ctactcgtcg cacaagggtg 780  
 actataatga cagcgtgcaa gttgtggact gtggactaag tctgaatgat actgcttttg 840  
 agaaaatgat catttcagaa ttagtgcaca acaacttacg gggcagcagc aagactcaca 900  
 acctcgagct cagcgtacca gtcaaacctg tgattggagg tagcagcagt gaagatgatg 960  
 ctattgtggc agatgcttca tctttaatgc acagcgacaa cccagggtcg gagctccatc 1020  
 40 acaagaact cgaggcacca cttattcctc agcggactca ctcccttctg taccaccccc 1080  
 agaagaaagt gaagtccgag ggaactgaca gctatgtctc ccaactgaca gcagaggctg 1140  
 aagatcacct acagtcccc aacagagact ctctttatac aagcatgccc aatcttagag 1200  
 actctcccta tccggagagc agccctgaca tggagaaga cctctctccc tccaggaggga 1260  
 gtgagaatga ggacatttac tataaaagca tgccaaatct tggagctggc catcagcttc 1320  
 agatgtgcta ccagatcagc aggggcaata gtgatgggtt tataatcccc attaacaagg 1380  
 aagggtgtat tccagaagga gatgttagag aaggacaaat gcagctgggt acaagtcttt 1440  
 45 aatcatacag ctaaggaatt ccaagggccca catgcgagta ttaataaata aagacaccat 1500  
 tggcctgacg cagctccctc aaactctgct tgaagagatg actcttgacc tgtggttctc 1560  
 tgggtgtaaaa aagatgactg aaccttgagc ttctgtgaat tttataaaa catacaaaaa 1620  
 ctttgtatat acacagagta tactaaagtg aattatttgt tacaagaaa agagatgcca 1680  
 gccagggtatt ttaagattct gctgctgttt agagaaattg tgaacaagc aaaacaaaac 1740  
 50 tttccagcca ttttactgca gcagctcttg aactaaattt gtaaatatgg ctgcaccatt 1800  
 tttgtaggcc tcattgttat acgtaggctt taaaatcctg tgggacaaat 1860  
 ttactgtacc ttactattcc tgacaagact tggaaaagca ggagagatat tctgcatcag 1920  
 tttgcagttc actgcaaatc ttttacatta aggcacaaat tgaaacatg cttaaccact 1980  
 agcaatcaag ccacaggcct tatttcataa gtttccctca ctgtacaatg aactattctc 2040  
 attgaaaaatg gctaaaagaaa ttatatattg aggttaaaat aaatacattt 2100  
 gtgtccaact gaaatataat tgtcattaaa ataattttta agagtgaaga aaatattgtg 2160  
 55 aaaagctctt gggtgcacat gttatgaaat gttttttctt acactttgtc atggttaagt 2220  
 ctactcattt tcacttcttt tccactgtat acagtgttct gctttgacaa agttagtctt 2280

EP 1 166 798 A1

5      tattactttac atttaaattt cttattgcca aaagaacgtg ttttatgggg agaaacaaac 2340  
       tctttgaagc cagttatgtc atgccttgca caaaagtgat gaaatctaga aaagattgtg 2400  
       tgtcacccct gtttattctt gaacagaggg caaagagggc actgggcact tctcacaac 2460  
       tttctagtga acaaaagggt cctattcttt tttaaaaaaa taaaataaaa cataaatatt 2520  
       actcttccat attccttctg cctatatatta gtaattaatt tattttatga taaagtctta 2580  
       atgaaatgta aattgtttca gcaaaattct gctttttttt catccctttg tgtaaacctg 2640  
       ttaataatga gccatcact aatatccagt gtaaagttta acacggtttg acagtaaata 2700  
       aatgtgaatt ttttcaagtt aaaaaaaaaa aa  
  
 10      <210> 19  
       <211> 276  
       <212> DNA  
       <213> Human  
  
       <400> 19  
  
 15      ctccctaata gatttttaaaa taaattggat aaacatatga tataaagtgg gtacttttaga 60  
       aaccgccttt gcatattttt tatgtacaaa tctttgtata caattccgat gttccttata 120  
       tattccctat atagcaaacc aaaaccagga cctcccaact gcatgcctca agtccctgtg 180  
       gagcactctg gcaactggat ggccctactt gctttctgac aaaatagctg gaaaggagga 240  
       gggaccaatt aaatacctcg gccgcgacca cgctgg  
  
 20      <210> 20  
       <211> 2361  
       <212> DNA  
       <213> Human  
  
       <400> 20  
  
 25      attgtaccag ccttgatgaa cgtgggccct gcttcgcttt tgaggggccat aagctcattg 60  
       cccactgggt tagaggctac cttatcattg tctcccgtag ccggaaggtt tctcccaagt 120  
       cagagtttac cagcagggat tcacagagct ccgacaagca gattctaaac atctatgacc 180  
       tgtgcaacaa gttcatagcc tatagcaccg tctttgagga tgtagtggat gtgcttgctg 240  
       agtggggctc cctgtacgtg ctgacgcggg atgggcgggt ccacgcactg caggagaagg 300  
       30      acacacagac caaactggag atgctgttta agaagaacct atttgagatg gcgattaacc 360  
       ttgccaagag ccagcatctg gacagtgatg ggctggccca gattttcatg cagtatggag 420  
       accatctcta cagcaagggc aaccacgatg gggctgtcca gcaatatatc cgaaccattg 480  
       gaaagtggga gccatcctac gtgatccgca agtttctgga tgcccagcgc attcacaacc 540  
       tgactgccta cctgcagacc ctgcaccgac aatccctggc caatgcccac cataccacc 600  
       tgctcctcaa ctgctatacc aagctcaagg acagctcgaa gctggaggag ttcatacaaga 660  
       35      aaaagagtga gagtgaagtc cactttgatg tggagacagc catcaaggtc ctccggcagg 720  
       ctggctacta ctcccattgc ctgtatctgg cggagaacca tgcacatcat gagtgggtacc 780  
       tgaagatcca gctagaagac attaagaatt atcaggaagc ccttcgatac atcggcaagc 840  
       tgccttttga gcaggcagag agcaacatga agcgtactcg caagatcctc atgcaccaca 900  
       taccagagca gacaactcag ttgctgaagg gactttgtac tgattatcgg ccagcctcg 960  
       aaggccgcag cgataggag gcccaggct gcagggccaa ctctgaggag ttcatcccca 1020  
       40      tctttgccaa taaccgcga gagctgaaag ccttcctaga gcacatgagt gaagtgcagc 1080  
       cagactcacc ccaggggatc tacgacacac tccttgagct gcgactgcag aactgggccc 1140  
       acgagaagga tccacaggtc aaagagaagc ttcacgcaga ggccatttcc ctgctgaaga 1200  
       gtggtcgctt ctgcgacgtc tttgacaagg ccctggctct gtgccagatg cagacttcc 1260  
       aggatgggtg cctttacctt tatgagcagg ggaagctgtt ccagcagatc atgcactacc 1320  
       acatgcagca cgagcagtac cggcagggtc tcagcgtgtg tgagcgcctat ggggagcagg 1380  
       45      acccctcctt gtgggagcag gccctcagct acttcgctcg caaggaggag gactgcaagg 1440  
       agtatgtggc agctgtcctc aagcatatcg agaacaagaa cctcatgccca cctcttctag 1500  
       tggtgcagac cctggcccac aactccacag ccacactctc cgtcatcagg gactacctgg 1560  
       tccaaaaact acagaaacag agccagcaga ttgcacagga tgagctgagg gtgcggcggt 1620  
       accgagagga gaccacccgt atccgccagg agatccaaga gctcaaggcc agtcctaaga 1680  
       ttttccaaaa gaccaagtgc agcatctgta acagtgcctt ggagttgccc tcagtccact 1740  
       50      tcctgtgtgg cactccttc caccaacact gctttgagag ttactcgga agtgatgctg 1800  
       actgcccac ctgcctcctt gaaaaccgga aggtcatgga tatgatccgg gccagggaac 1860  
       agaaacgaga tctccatgat caattccagc atcagctcaa gtgctccaat gacagctttt 1920  
       ctgtgattgc tgactacttt ggcagaggtt ttttcaacaa attgactctg ctgaccgacc 1980  
       ctccacagc cagactgacc tccagcctgg aggtggggt gcaacgcgac ctactcatgc 2040  
       actccaggag gggcacttaa gcagcctgga ggaagatgtg ggcaacagtg gaggaccaag 2100  
       55      agaacagaca caatgggacc tgggcgggcg ttacacagaa ggctggctga catgccagg 2160  
       gctccactct catctaatgt cacagccctc acaagactaa agcggaactt tttcttttcc 2220

EP 1 166 798 A1

ctggccttcc ttaattttta gtcaagcttg gcaatccctt cctcttttaac taggcaggtg 2280  
 ttagaatcat ttccagatta atggggggga aggggaacct caggcaaacc tcctgaagtt 2340  
 ttgaaaaaaa aagctggttt c

5  
 <210> 21  
 <211> 179  
 <212> DNA  
 <213> Human

10  
 <400> 21

aggtgttaga tgctcttgaa aaagaaactg catctaagct gtcagaaatg gattctttta 60  
 acaatcaact aaaggaactg agagaaacct acaacacaca gcagttagcc cttgaacagc 120  
 tttataagat caacgtgaca agttgaagga aattgaaagg aaaaaattag aactaatgc

15  
 <210> 22  
 <211> 905  
 <212> DNA  
 <213> Human

<400> 22

20  
 tttttttttt ttctttaacc gtgtggtctt tatttcagtg ccagtggttac agatacaaca 60  
 caaatgttcc agttagaagg aattcaaacg gaatgccaag gtccaagcca ggctcaagaa 120  
 ataaaaaggg aggtttggag taatagataa gatgactcca atactcactc ttccacccat 180  
 caaaggtact tttgatacag agtctgatct ttgaaactgg tgaactcctc ttccacccat 240  
 taccatagtt caaacaggca agttatgggc ttaggagcac tttaaaattt gtggtgggaa 300  
 tagggtcatt aataactatg aatatacttt ttagaagggt accattttgc actttaaagg 360  
 gaatcaattt tgaatatcat ggagactatt catgactaca gctaaagaat ggcgagaaag 420  
 gggagctgga agagccttgg aagtttctat tacaaataga gcaccatata cttcatgcca 480  
 aatctcaaca aaagctcttt ttaactccat ctgtccagtg tttacaaata aactcgcaag 540  
 gtctgaccag ttcttggtaa caaacataca tgtgtgtgtc tgtgtgtata cagcaatgca 600  
 cagaaaaggc taccaggagc ctaatgcctc tttcaaacat tgggggaacc agtagaaaaa 660  
 ggcagggtct cctaattgtc attattacat ttccattccg aatgccagat gttaaaagtg 720  
 cctgaagatg gtaacccagc tagtgaggaa taaatacccc accttgccca gtccacagag 780  
 aaacaacagt agaagaagg ggcaactctt tgctgcagag acaaaagtga tgttttttcg 840  
 ccatggattg cagtctcttc ctccagacca gctgcttatt tctcagggg cccagggaat 900  
 gttga

35  
 <210> 23  
 <211> 2134  
 <212> DNA  
 <213> Human

<400> 23

40  
 ggtctcttct ttcttttttt tttttccaaa agtgttcttt tatttctagt aacatatatt 60  
 gtataaatac tctattttat atgcacttcc acaaaagcga tataatttta aagttttttt 120  
 cattagaaat aaatgtataa aaataaatat gttattatag gcattttatta ctaactatag 180  
 tccttcttgg aaggaacacc caaaccaata cttataaagt acatgtaatt tatagtaaca 240  
 tattttacta tatacatatg gaaaaaatca tattctcaca gaagagctga acagacattc 300  
 accaggatac gactgttgga ccagctgctg gagatggacc tgctaccctc cagcagcctc 360  
 cccaccacaa gacaagtgat ctcaatgtcc ccaaacctgt gggaccctgt tctacacacc 420  
 tcatttttgt tccggcggtt catcctcctt gtgtgattgt actgattttc atgagacaca 480  
 agttacttct ttacatccat attcccaaag cagggttaca tggtaggaaa gaaaggaaag 540  
 tggaggtact aagctcattg tgtctcctct agcttttacc agcatctaat gcttcaactgc 600  
 tttttttcca ttgtagactt taatgcactt gaataaatac atggagtgtt tttttcctca 660  
 aaatgaatta cacaaataaa gactgagatg gtccaaaaaa ggaaagagga agccatttgc 720  
 gttatttcac gttgctgagc cttctctca tgttgaacaa tctgaagttt taattctcgg 780  
 tagaaataat gtataaacat tctctgaaac catagcagcc ataaacagtg ctggtcaaag 840  
 atcctatttg tactcctttc tccccccatt gttagtggag taaagtaaaa cagggtcttag 900  
 taaaatctca cttttctcct acttttcatt tcccaacccc catgatacta agtattttgat 960  
 aagtaccagg aaacaggggt tgtaatatgt ctaacttttt ttgacaattg ctttgttttt 1020  
 tctaaacttg taatagatgt aacaaaagaa ataataataa taatgcccgg ggctttatta 1080  
 tgctatatca ctgctcagag gttataaatc ctcactaact atcctatcaa atttgcaact 1140  
 ggcagtttac tctgatgatt caactccttt tctatctacc cccataatcc caccttactg 1200

55

EP 1 166 798 A1

5 ataccacctca ctggttactg gcaagatacg ctggatccct ccagccttct tgctttccct 1260  
 gcaccagccc ttccctcactt tgccctgccc tcaaaagctaa caccacttaa accacttaac 1320  
 tgcattctgc cattgtgcaa aagtctatga aatgttttagg tttctttaaa ggatcacagc 1380  
 tctcatgaga taacaccctt ccacatgagg acagacactt caagcttctt tttttgtaac 1440  
 ccttcccaca ggtcttagaa catgatgacc actccccag ctgccactgg gggcagggat 1500  
 ggtctgcaca aggtctggtg ctggctggct tcaacttcctt tgcacactcg gaagcaggct 1560  
 gtccattaat gtctcggcat tctaccagtc ttctctgcca acccaattca catgacttag 1620  
 aacattcgcc ccactcttca atgacccatg ctgaaaaagt ggggatagca ttgaaagatt 1680  
 10 ccttcttctt ctttacgaag taggtgtatt taatttttagg tcgaagggca ttgccacag 1740  
 taagaacctg gatggtcaag ggctctttga gagggctaaa gctgcgaatt ctttccaatg 1800  
 ccgcagagga gccgctgtac ctcaagacaa cacctttgta cataatgtct tgctctaagg 1860  
 tggacaaagt gtagtcacca ttaagaatat atgtgccatc agcagctttg atggcaagaa 1920  
 agctgctttt tactgatact aaatgttggt tccgctggtt cacttcgatg ttggtggctc 1980  
 cagttggaat tgtgatgata tcatgatatc caggttttgc actagtaact gatcctgata 2040  
 tttttttaca agtagatcca tttccccgc aaacaccaca tttatcaaac ttctttttgg 2100  
 15 agtctatgat gcgatcacia ccagctttta caca

<210> 24  
 <211> 1626  
 <212> DNA  
 <213> Human

20 <400> 24

ggacaatttc tagaatctat agtagtatca ggatatattt tgctttaaaa tatattttgg 60  
 ttattttgaa tacagacatt ggctccaaat tttcatcttt gcacaatagt atgacttttc 120  
 25 actagaactt ctcaacattt gggaactttg caaatatgag catcatatgt gtttaaggctg 180  
 tatcatttaa tgctatgaga tacattgttt tctccctatg ccaaacaggt gaacaaacgt 240  
 agttgttttt tactgatact aaatgttggt tactctgtat tttatagtat gcacatgtca 300  
 gaaaaaggca agacaaatgg cctctgttac tgaatacttc ggcaaaactta ttgggtcttc 360  
 atttctctgac agacaggatt tgactcaata tttgtagagc ttgctgtagaa tggattacat 420  
 ggtagtgtatg cactggtaga aatggttttt agttattgac tcagaattca tctcaggatg 480  
 aatcttttat gtctttttat tgtaagcata tctgaattta ctttataaag atggtttttag 540  
 30 aaagctttgt ctaaaaaattt ggcttaggaa tggtaacttc attttcagtt gccaaaggggt 600  
 agaaaaataa tatgtgtgtt gttatgttta tgtaaacata ttattaggta ctatctatga 660  
 atgtatttaa atatttttca tattctgtga caagcattta taatttgcaa caagtggagt 720  
 ccatttagcc cagtgggaaa gtcttggaac tcagggttacc cttgaaggat atgctggcag 780  
 ccattctctt gatctgtgct taaactgtaa tttatagacc agctaaatcc ctaacttgga 840  
 tctggaatgc attagttatg ccttgtagca tcccagaat ttcaaggggca tcgtgggttt 900  
 35 ggtctagtga ttgaaaacac aagaacagag agatccagct gaaaaagagt gatcctcaat 960  
 atcctaacta actggtcctc aactcaagca gagtttcttc actctggcac tgtgatcatg 1020  
 aaacttagta gaggggattg tgtgtatttt atacaaattt aatacaatgt cttacattga 1080  
 taaaattctt aaagagcaaa actgcatttt atttctgcat ccacattcca atcatattag 1140  
 aactaagata tttatctatg aagataataa tgggtgcagag agactttcat ctgtggattg 1200  
 cggtgtttct tagggttcct agcactgatg cctgcacaag catgtgatat gtgaaataaa 1260  
 40 atggattcct ctatagctaa atgagttccc tctggggaga gttctgggtac tgcaatcaca 1320  
 atgccagatg gtgtttatgg gctattttgtg taagtaagt gtaagatgct atgaagtaag 1380  
 tgtgtttgtt ttcattctat ggaaactctt gatgcatgtg cttttgtatg gaataaaatt 1440  
 tgggtgcaata tgatgtcatt caactttgca ttgaattgaa ttttggttgt atttatatgt 1500  
 attatacctg tcacgcttct agttgttcca accattttat aaccattttt gtacatattt 1560  
 tacttgaaaa tatttttaaat ggaaatttaa ataaacattt gatagtttac ataataaaaa 1620  
 45 aaaaaa

<210> 25  
 <211> 1420  
 <212> DNA  
 <213> Human

50 <400> 25

gttcagcatt gtttctgctt ctgaaatctg tatagtacac tgggtttgtaa tcattatgtc 60  
 ttcattgaaa tccttgctac ttctcttctt cctcaatgaa agacacgaga gacaagagcg 120  
 55 acacaagctt aagaaaaacg agcaaggaag agtatcttca ttattctcat tttctctgag 180  
 ttggaacaaa aaacatgaag gactccaact agaagacaga tatttacatt taaatagatt 240  
 agtgggaaaa ctttaagagt ttccacatat tagttttcat tttttgagtc aagagactgc 300  
 tccttgatct gggagacact agtagtatat gtttgtaatg ttactttaaa attatctttt 360

EP 1 166 798 A1

5 tattttataa ggcccataaa tactgggttaa actctgttaa aagtgggcct tctatcttgg 420  
 atgggtttcac tgccatcagc catgctgata tattagaaat ggcatcccta tctacttact 480  
 ttaatgctta aaattataca taaatgctt tatttagaaa acctacatga tacagtgggtg 540  
 tcagccttgc catgtatcag ttccacttga aatttgagac caattaaatt tcaactgttt 600  
 aggggtggaga aagaggtact ggaaaacatg cagatgagga tatcttttat gtgcaacagt 660  
 atcctttgca tgggaggaga gttactcttg aaagcgaggc agcttaagtg gacaatgttt 720  
 tgtatatagt tgagaatttt acgacacttt taaaaattgt gtaattgtta aatgtccagt 780  
 tttgctctgt tttgcctgaa gtttttagtat ttgttttcta ggtggacctc tgaataccaa 840  
 10 accagtacct ggggaggtta gatgtgtgtt tcaggccttg agtgtatgag tgggttttgc 900  
 tgtatttttc tccagagatt ttgaacttta ataattgcgt gtgtgttttt ttttttttaa 960  
 gtggccttgt ttttttttct caagtaaaat tgtgaacata tttcctttat aggggcaggg 1020  
 catgagttag ggagactgaa gagtattgta gactgtacat gtgccttctt aatgtgtttc 1080  
 tcgacacatt ttttttcagt aacttgaaaa ttcaaaaagg acatttgggt aggttactgt 1140  
 acatcaatct atgcataaat ggcagcttgt tttcttgagc cactgtctaa atttgtttt 1200  
 tataaaaatt ttttatactg attggttcac agatggtcag tttgttacac agactgaaca 1260  
 15 atacagcact ttgccaaaaa tgagtgtagc attgtttaaa cattgtgtgt taacacctgt 1320  
 tctttgtaat tgggttgggg tgcattttgc actacctgga gttacagttt tcaatctgtc 1380  
 agtaataaaa gtgtccttta acttcaaaaa aaaaaaaaaa  
  
 <210> 26  
 <211> 689  
 <212> DNA  
 <213> Human  
  
 <400> 26  
  
 25 aaacaaacaa aaaaaaagtt agtactgtat atgtaaatag tagcttttca atgtgctata 60  
 caaacaatta tagcacatcc ttccttttac tctgtctcac ctcccttagg tgagtacttc 120  
 cttaaataag tgctaatacat acatatacgg aacttgaaaag ctttgggttag ccttgcccta 180  
 ggtaatcagc ctagttttaca ctgtttccag ggagtagttg aattactata aaccattagc 240  
 cacttgtctc tgcaccattt atcacaccag gacagggtct ctcaacctgg gcgctactgt 300  
 catttggggc caggtgattc ttccttgcaa gggctgtcct gtacctgccg gggcgccgcg 360  
 30 tcgaagcgtg gtcgcggccg aggtactgaa aggaccaagg agctctggct gccctcagga 420  
 attccaaatg accgaaggaa caaagcttca gggctctggg tgggtgtctc cactattcag 480  
 gaggtgggtc gaggtaacgc agcttcattt cgtccagtc tttccagtat ttaaagtgt 540  
 tgtcaagatg ctgcattaaa tcaggcaggt ctacaaaggc atcccaagca tcaaacatgt 600  
 ctgtgatgaa gtaatacatg aaacaccgga acctccgacc acctcctgaa tagtgggaga 660  
 cacaccacga gcctgaagtt tgtccttcg  
  
 <210> 27  
 <211> 471  
 <212> DNA  
 <213> Human  
  
 <400> 27  
  
 40 tcccagcggc atgaagtttg agattggcca ggccctgtac ctgggcttca tctccttcgt 60  
 ccctctcgtc catttgggtgg accctgcttt gcctgtcctg ccaggacgag gcaccctaca 120  
 agccctaacc caggcccccgc ccaggggccac cagcaccact gcaaacaccg cacctgccta 180  
 ccagccacca gctgcctaca aagacaatcg ggcacctca gtgacctcgg ccaccacagc 240  
 gggtagcaggc tgaacgacta cgtgtgagtc cccacagcct gcttctcccc tgggctgctg 300  
 45 tgggctgggt cccggcgggg ctgtcaatgg aggcaggggg tccagcacaa agtttacttc 360  
 tgggcaattt ttgtatccaa ggaaataatg tgaatgcgag gaaatgtctt tagagcacag 420  
 ggacagaggg ggaaataaga ggaggagaaa gctctctata ccaaagactg a  
  
 <210> 28  
 <211> 929  
 <212> DNA  
 <213> Human  
  
 <400> 28  
  
 55 ggtgaactca gtgcattggg ccaatggttc gacacaggct ctgccagcca caaccatcct 60  
 gctgcttctg acggtttggc tgctgggtgg ctttccctc actgtcattg gaggcattct 120  
 tgggaagaac aacgccagcc cctttgatgc accctgtcgc accaagaaca tcgccgggga 180  
 gattccaccc cagccctggg acaagctctac tgtcatccac atgactgttg gaggttctct 240

EP 1 166 798 A1

5 gcctttcagt gccatctctg tggagctgta ctacatcttt gccacagtat ggggtcggga 300  
 gcagtacact ttgtacggca tctctctctt tgtcttcgcc atcctgctga gtgtgggggc 360  
 ttgcatctcc attgcaactca cctacttcca gttgtctggg gaggattacc gctgggtggg 420  
 gcgatctgtg ctgagtgttg gctccacogt cctcttcac ttctctact cagttttcta 480  
 ttatgcccg cgctccaaca tgtctggggc agtacagaca gtagagttct tcggctactc 540  
 ctactcact ggttatgtct tcttcctcat gctgggcacc atctcctttt tttcttcctt 600  
 aaagtctatc cggatatatct atgttaacct caagatggac tgagtctctg atggcagaac 660  
 tattgtctgt ctctcccttt cttcatgccc tgttgaactc tctaccagc ttctctctctg 720  
 attgactgaa ttgtgtgatg gcattgttgc cttccctttt tccctttggg cattccttcc 780  
 10 ccagagaggg cctggaaatt ataaatctct atcacataag gattatatat ttgaactttt 840  
 taagttgcct ttagtttttg tcttgatttt tctttttaca attacaaaaa taaaatttat 900  
 taagaaaaag aaaaaaaaaa aaaaaaaaaa  
  
 <210> 29  
 <211> 1775  
 <212> DNA  
 15 <213> Human  
  
 <400> 29  
  
 20 gaacgtgatg ggaacttttg gaggatgtct gagaaaaatgt ccgaagggat tttggccaac 60  
 accagaaaaac gccaatgtcc taggaattcc ctcccaaaat gcttcccaaa aaattactca 120  
 ttgacaattc aaattgcact tggctggcgg cagcccgggc ggcttccagt ccgtgtgggg 180  
 cgcccgctg gccttctcct cgtaggactc cccaaactcg ttactctgc gtttatccac 240  
 aggataaaag caccgctggt acaggtagac cagaaacacc acgtcgtccc ggaagcaggc 300  
 cagccggtga gacgtgggca tgggtgatgat gaaggcaaaag acgtcatcaa tgaagggtgtt 360  
 gaaagccttg taggtgaagg ccttcacagg cagatgtgcc actgacttca acttgtagtt 420  
 25 cacaaaagagc tggggcagca tgaagaggaa accaaaggca tagaccccg tgcggaagct 480  
 gttgattaac caggagtacc agctcttata tttgatattc aggagtgaat agacagcacc 540  
 cccgacacag agagggtaca gcaggtatga caagtacttc atggcctgag tatcgtactc 600  
 ctcggttttc ctctcagatt cgctgtaagt gccaaactga aattcgggca tcaggcctct 660  
 ccaaaaaata gtcattctta atgccttctt cactttccac agctcaatgg cggctccaac 720  
 acccgccggg accagcacca gcaggctcgt ctgctcgtcc agcaggaaca gaaagatgac 780  
 30 cacgggtgctg aagcagcgcc agagcactgc cttgggtggac atgccgatca tgctcttctt 840  
 cttcttccag aaactgatgt cattttttaa ggccaggaaa tcaaagagaa gatggaacgc 900  
 tgcgacaaag aaggtcagcg ccagggaagta taagttggta tctacaaaaa ttctttccac 960  
 ctcatcagca tctttctctg aaaaccgcaa ctgctgcagg gagtacacgg cgtcctgcat 1020  
 gtggatccag aagcgcagcc gccccagtga gaccttgcg taggacacgg tgaggggcag 1080  
 ctcgggtggtg gagcggttta tgaccatcag gtccttcacg cggttgctga gctgggtcgt 1140  
 35 gaacaggatg ggcaggtaat gcacggtttt ccccagctgg atcatcttca tgtaccgatg 1200  
 cacatcgcca ggcagggagg acccgctcaa gacaaagtgt tccgccatca cgttcagcgc 1260  
 cagcccggt cgccagtggt acactggctc atccagggca ctcgctcggt tcttctccgc 1320  
 ctcgatctgc tgtgtatcag actccccggt gagcagggtt atttcttctg gcttggggac 1380  
 catgtaggtg gtcagaggac tgaccagggt cacctgcttc ccgtcgtgcc acggcaggac 1440  
 cccagcgtga tggaggaaga tgtaggcata cagcgtccca ttgtttctcg tttcttttg 1500  
 40 tacagaaaca ttaactgtcc tttcaaattt ggactccaca tcaaagtctt ccacattcaa 1560  
 gaccaggtcg atgttgttct cagcaccacag gtgggacctc gtcgtggtgt acacgctcag 1620  
 ctgcagcttg ggcgcccgcg ccaggtaggg ctggatgcag ttggcgtcgc cggagcacgg 1680  
 gcgggtgtag acgatgccgt acatgacca gcaggtgtgc accacgtaga ccacgaacac 1740  
 gccaccacc aagctggtga aggagctgcg gcccc  
  
 <210> 30  
 <211> 1546  
 <212> DNA  
 <213> Human  
  
 <400> 30  
  
 50 aaaataagta ggaatgggca gtgggtattc acattcacta cactttttcc atttgctaatt 60  
  
 aaggccctgc caggctggga gggaattgtc cctgcctgct tctggagaaa gaagatattg 120  
 acaccatcta cgggcacccat ggaactgctt caagtaccca ttctttttct tctgccaggt 180  
 atttgacaga gtaacagcac aggtgtttta gaggcagcta ataattcact tgttggtact 240  
 55 acaacaaaac catctataac aacaccaaac acagaatcat tacagaaaaa tgttgtcaca 300  
 ccaacaactg gaacaactcc taaaggaaca atcaccaatg aattacttaa aatgtctctg 360  
 atgtcaacag ctactttttt aacaagtaaa gatgaaggat tgaaagccac aaccactgat 420



5 gtcaggaaga atgactccat catttcaaac gtaacagtaa caagtgttac acttccaaat 480  
 gctgtttcaa cattacaaag ttccaaaccc aagactgaaa ctcagagttc aattaaaaa 540  
 acagaaatac caggtagtgt tctacaacca gatgcacac cttctaaaac tggtagatta 600  
 acctcaatac cagttacaat tccagaaaac acctcacagt ctcaagtaat aggcactgag 660  
 ggtggaaaaa atgcaagcac ttcagcaacc agccggtctt attccagtat tttttgccc 720  
 gtggttattg ctttgattgt aataacactt tcagtatttg ttctgggtggg tttgtaccga 780  
 atgtgctgga aggcagatcc gggcacacca gaaaatggaa atgatcaacc tcagtctgat 840  
 aaagagagcg tgaagcttct taccgttaag acaattttct atgagtctgg tgagcactct 900  
 gcacaaggaa aaaccaagaa ctgacagctt gaggaattct ctccacacct aggcataat 960  
 10 tacgcttaat cttcagcttc tatgcaccaa gcgtggaaaa ggagaaagtc ctgcagaatc 1020  
 aatcccagact tccatacctg ctgctggact gtaccagacg tctgtcccag taaagtgtatg 1080  
 tccagctgac atgcaataat ttgatggaat caaaaagaac cccggggctc tcctgttctc 1140  
 tcacatttaa aaattccatt actccattta caggagcgtt cctaggaaaa ggaatttttag 1200  
 gaggaagaatt tgtgagcagt gaatctgaca gcccaggagg tgggctcgct gataggcatg 1260  
 actttcctta atgtttaaag ttttccgggc caagaatttt tatccatgaa gactttccta 1320  
 15 cttttctctg ttctcttata ttactactg ttagtattta ttgtttacca ctatgttaat 1380  
 gcagggaaaa gttgcacgtg tattattaaa tattaggtag aaatcatacc atgctacttt 1440  
 gtacatatata gtattttatt cctgctttcg tgttactttt aataaataac tactgtactc 1500  
 aatactctaa aaatactata acatgactgt gaaaatggca aaaaaa  
  
 <210> 31  
 <211> 750  
 20 <212> DNA  
 <213> Human  
  
 <400> 31  
  
 25 cacttgggca cccccatttt ctaaaaaat ggaaatctgg agggcaaaaa aggtgtgctg 60  
 aagggaagtg cctctgatgg cccaaaaacc ttcttccaaa ctagtgtagg aatggaatgg 120  
 atagcaaatg gatccttttt ggccctcctt ggagcatgcc ttccctatct tatccttggc 180  
 cccactaaag cagaacgtta cggatatttc tgtttttgcc attggatgcc tatctggcca 240  
 aacagccttt ccctaattgg aaaaatgcagt cctgtttaaa acctttgatt tacgactact 300  
 tgtacatgct tgctcattac aattttgaca ttttttacct agtgaagacc ccaaacatat 360  
 30 cagtgaacaa tgacaagatc ataaagaaca gtatcatatt attatttagt cgcttttaca 420  
 gtggcaagcc aattttgaaa tatctcattt aaaactcaga cccaattcac tgagtatac 480  
 ttttaatagc ttctcagca cactatttcc catgcattaa atagataaa ataactctac 540  
 actgcccacg ggtcttgtaa aaaggaagtc tgaatacaga gccacaaca ctaaaattgt 600  
 ttttctagct acaaagtata gcatcatcaa cacagacacg atttggaactc cctgacaggt 660  
 ggattggaaa acggtgttta aagagaagag aacattttta cataaatgtc attaagaatc 720  
 35 ccaaaggcct tatttgtcac caccgtcccg  
  
 <210> 32  
 <211> 1620  
 <212> DNA  
 <213> Human  
  
 40 <400> 32  
  
 gcaattcccc cctccacta aacgactccc agtaattatg tttacaaccc attggatgca 60  
 gtgcagccat tcataagaac cttggtgccc cagaaaaatc tgtccttttt ggtaccaaac 120  
 ctgaggtctt ttggaagata atgtagaaaa ccactaccta ttgaaggcct gttttggcta 180  
 45 atctgtgcaa actctgatga tacctgcctt atgtggattc tttccacac tgctttcatt 240  
 ttttaagtata aagacttaga aaactagaat aatgctttta caaataatta aaagtatgtg 300  
 atgttctggg ttttttctt ctttttagaa ccccgctcc atttaaaaaa ttaaaaaaaa 360  
 aaaaaaaact tttaacattt aaaaaataaa aattaacaaa atttcaacta ttccaggaca 420  
 cgctggcatt tggactcaat gaaaagggca cctaaagaaa ataaggctga ctgaatgttt 480  
 tccataatth tcacacaata acagtccctt tctatccagc ttgccttcca tttatctcta 540  
 ggggttagctt ttacaggcaac atccttggtc attgcccaga aagtacctga gctatcagtg 600  
 50 attggaatgg cacaggaaac cgaatcacat ggtgcccctc cccttggttt tcaagtatct 660  
 tggagttgtg cacaaaaatt aggtcatgcc ttcagtgtct tgttctttta acctaccctt 720  
 tgacaatcag gtgctaataa ttgtatacta ttaaaaccag cacataagta ttgtaaatgt 780  
 gtgttctctc tttagttgaa gaaatgtctt tccttctatc tgggtcctgt taaagcgggt 840  
 gtcagttgtg tcttttcacc tctgatttgt aattaataga attgggggga gaggaatga 900  
 tgatgtcaat taagtttcag gtttggcatg atcatcattc tctgatgat tctcactttg 960  
 55 tgcgaaatct gcccttatcg taagaacaag ttccagaatt ttccctccac tatacgaactc 1020  
 cagtattatg tttacaatcc attggatgag tgcagcatta taagaccttg gtgcccagaa 1080

EP 1 166 798 A1

5      aaatctgtcc    tttttggtac    caaacctgag    gtcttttga    agataatgta    gaaaaccact    1140  
       acctattgaa    ggctgtgttt    ggctaactct    tgcaaactct    gatgatacct    gcttatgtgg    1200  
       attcttttcc    acactgcttt    catttttaag    tataaagact    tagaaaacta    gaataatgct    1260  
       tttacaata    attaaaagta    tgtgatgttc    tgggtttttt    ctttcttttt    agaaccctgt    1320  
       atttaaacaa    gccttctttt    taagtcttgt    ttgaaattta    agtctcagat    cttctggata    1380  
       ccaaatcaaa    aacccaacgc    gtaaaacagg    gcagtatttg    tgttcctaata    tttaaaaagc    1440  
       tttatgtata    ctctataaat    atagatgcat    aaacaacact    tccccttgag    tagcacatca    1500  
       acatacagca    ttgtacatta    caatgaaaat    gtgtaactta    agggatttat    atatataaat    1560  
       acatatatac    ctttgtaacc    tttatactgt    aaataaaaaa    gttgctttag    tcaaaaaaaa    1620  
  
 10      <210> 33  
       <211> 2968  
       <212> DNA  
       <213> Human  
  
 15      <400> 33  
  
 20      gaaaaagtag    aaggaaacac    agttcatata    gaagtaaaag    aaaaccctga    agaggaggag    60  
       gaggagggaag    aagagggaaga    agaagatgaa    gaaagtgaag    aggaggagga    agaggaggga    120  
       gaaagtgaag    gcagtgaagg    tgatgaggaa    gatgaaaagg    tgtcagatga    gaaggattca    180  
       gggaagacat    tgataaaaaa    gccaaagtaa    gaaatgagct    cagattctga    atatgactct    240  
       gatgatgac    ggactaaaga    agaaaagggt    tatgacaaag    caaaacggag    gattgagaaa    300  
       cggcgacttg    aacatagtaa    aaatgtaaac    accgaaaagc    taagagcccc    tattatctgc    360  
       gtacttgggc    atgtggacac    agggaagaca    aaaattctag    ataagctccg    tcacacacat    420  
       gtacaagatg    gtgaagcagg    tggatcacaca    caacaaattg    gggccaccaa    tgttcctctt    480  
       gaagctatta    atgaacagac    taagatgatt    aaaaattttg    atagagagaa    tgtacggatt    540  
       ccaggaaatgc    taattattga    tactcctggg    catgaatctt    tcagtaatct    gagaaataga    600  
       ggaagctctc    tttgtgacat    tgccatttta    gttgttgata    ttatgcatgg    tttggagccc    660  
 25      cagacaattg    agtctatcaa    ctttctcaaa    tctaaaaaat    gtcccttcat    tgttgactct    720  
       aataagattg    ataggttata    tgattggaag    aagagtcctg    actctgatgt    ggctgctact    780  
       ttaaagaagc    agaaaaagaa    tacaaaagat    gaatttgagg    agcgagcaaa    ggctattatt    840  
       gtagaatttg    cacagcaggg    tttgaatgct    gctttgtttt    atgagaataa    agatccccgc    900  
       acttttgtgt    ctttggtacc    tactctgca    catactgggt    atggcatggg    aagctctgac    960  
       taccttcttg    tagagttaac    tcagaccatg    ttgagcaaga    gacttgcaca    ctgtgaagag    1020  
       ctgagagcac    aggtgatgga    gggttaaagct    ctcccgggga    tgggcaaccac    tatagatgtc    1080  
       atcttgatca    attggcgctt    gaagggaagg    gatacaatca    ttgttctctg    agtagaaggg    1140  
       cccattgtaa    ctcagattcg    aggcctcctg    ttacctctct    ctatgaagga    attacgatgt    1200  
       aagaaccagt    atgaaaagca    taaagaagta    gaagcagctc    aggggggtaa    gattcttgga    1260  
       aaagacctgg    agaaaaacatt    ggctggttta    cccctccttg    tggcttataa    agaagatgaa    1320  
       atccctgttc    taaagatga    attgatccat    gagttaaagc    agacactaaa    tgctatcaaa    1380  
 35      ttagaagaaa    aaggagtcta    tgtccaggca    tctacactgg    gttctttgga    agctctactg    1440  
       gaatttctga    aaacatcaga    agtgccttat    gcaggaaatta    acattggccc    agtgcataaa    1500  
       aaagatgtta    tgaaggcttc    agtgccttat    gaacatgacc    ctgagatgac    agtaattttg    1560  
       gccttcgagt    tgagaattga    acgagatgca    caagaaatgg    ctgagatgtt    aggagttaga    1620  
       atttttagtg    cagaaattat    ttatcattta    tttgatgcct    ttacaaaata    tagacaagac    1680  
       tacaagaaac    agaaacaaga    agaatttaag    cacatagcag    tatttccctg    caagataaaa    1740  
       atcctccctc    agtacatttt    taattctcga    gatccgatat    tgatgggggt    gacgggtgaa    1800  
       gcaggtcagg    tgaacacagg    gacacccatg    tgtgtcccaa    gcaaaaattt    tgttgacatc    1860  
       ggaatagtaa    caagtattga    aataaacatc    aaacaagtgg    atgttgcaaa    aaaaggacaa    1920  
       gaagtttgtg    taaaaataga    acctatccct    ggtgagtcac    ccaaaatggt    tgggaagacat    1980  
       tttgaagcta    cagatattct    tgttagtaag    atcagccggc    agtccattga    tgcaactcaa    2040  
       gactggttca    gagatgaaat    gcagaagagt    gactggcagc    ttatttgtga    gctgaagaaa    2100  
 45      gtatttgaaa    tcatctaatt    ttttcacatg    gagcaggaac    tggagttaaa    gcaatactgt    2160  
       gttgtaatat    cccaacaaaa    atcagacaaa    aaatggaaca    gacgtatttg    gacactgatg    2220  
       gacttaagta    tgggaaggaa    aaaaataggt    gtataaaatg    ttttccatga    gaaaccaaga    2280  
       aacttacact    ggtttgacag    tggtcagtta    catgtcccca    cagttccaat    gtgcctgttc    2340  
       actcacctct    cccttcccca    acccttctct    acttggctgc    tgttttaaag    tttgcccttc    2400  
       cccaaatttg    gattttttatt    acagatctaa    agctctttcg    attttatact    gattaaatca    2460  
 50      gtactgcagt    atttgattaa    aaaaaaaaat    gcagattttg    tgattcttgg    gacttttttg    2520  
       acgtaagaaa    tacttcttta    tttatgcata    ttcttcccac    agtgattttt    ccagcatctc    2580  
       tctgccatat    gccttttagg    cttttataaa    atagaaaatt    aggcattctg    atatttcttt    2640  
       agctgctttg    tgtgaaacca    tgggtgaaaa    gcacagctgg    ctgcttttta    ctgcttgtgt    2700  
       agtcaccgag    caattgtaat    ctgttaggct    ctacaacatt    ctaccaataa    agaaaacaga    2760  
       catccaccag    taagcaagct    ctgttaggct    tccatgggta    gtggtagctt    ctctcccaaa    2820  
 55      agttgtcctc    ctaggacaag    gaattatctt    aacaaaacta    actatccatc    aactacctt    2880  
       ggtatgccag    cacctgggta    acagtaggag    attttatata    ttaatctgat    ctgtttaatc    2940

tgatcggttt agtagagatt ttatacat

<210> 34  
 <211> 6011  
 <212> DNA  
 <213> Human

<400> 34

10

15

20

25

30

35

40

45

50

55

```

acggggcgcc ggacgacccg cacatcttat cctccacgcc ccaactcgac tcggagcggg 60
accgcccccg actccccctc gggccggcca ctcgaggagt gaggagagag gccgccggcc 120
cggcttgagc cgagcgcagc accccccgcg ccccgcgcca gaagtttggg tgaaccgggc 180
tgccgggaga aacttttttc ttttttcccc ctctcccggg agagtctctg gaggaggagg 240
ggaactcccc cggtcccaagg ctctggggct cggggtcgcg cggccgcaga aggggcgggg 300
tccgccccgc aggggagcg cccccggga cccgagaggg gggtagaggac cgcgggctgc 360
tggtgcggcg gcggcagcgt gtgccccgcg caggggaggc gccgccccgc tccggccccg 420
gctgcgagga ggagcgcgcg gcgcgcgagg aggatgtact tggtagcggg ggacaggggg 480
ttggcgggct gcgggcacct cctggtctcg ctgctggggc tgctgtctgt gccggcgcg 540
tccggcaacc gggcgctggg ctgctgccc tgtgacgagt ccaagtgcga ggagcccagg 600
aaccgccccg ggagcatcgt gcagggcgctc tgcggctgct gctacacgtg gccagccag 660
gggaacgaga gctgcggcg cgacctcggg atttacggaa cctgcgaccg ggggctgcgt 720
tgtgtcatcc gcccccgct caatggcgac tccctcaccg agtacgaagc gggcggttgc 780
gaagatgaga actggactga tgaccaactg cttggtttta aaccatgcaa tgaaaacctt 840
attgtcggct gcaatataat caatgggaaa tgtgaatgta acaccattcg aacctgcagc 900
aatccctttg agtttccaa ggcagatagc tgcctttcag ctttaaagag aattgaagaa 960
gagaagccag attgtccaa ggcccgctgt gaagtccagt tctctccacg ttgtcctgaa 1020
gattctgttc tgatcgaggg ttatgtcct cctggggagt gctgtccctt acccagccgc 1080
tgctgtgca accccgcagg ctgtctgcgc aaagtctgcc agccgggaaa cctgaacata 1140
ctagtgtcaa aagcctcagg gaagccggga gagtctgtg acctctatga gtgcaaccca 1200
gttttcggcg tggactgcag gactgtggaa tgccctactg ttcagcagac cgcgtgtccc 1260
ccggcacagt atgaaactca agtcagacta actgcagatg gttgctgtac ttggcaaca 1320
agatgcgagt gtctctctgg ctatgtggg ttcccgctgt gtgaggtggg atccactccc 1380
cgcatagtct ctggtgcga tgggacacct ggaagtgtgt gtgatgtctt tgaatgtgtt 1440
aatgatacaa agccagcctg cgtatttaac aatgtggaat attatgatgg agacatgttt 1500
cgaatggaca actgtcggtt ctgtcgatgc caagggggcg ttgccatctg cttcaccgcc 1560
cagtgtggtg agataaactg cgagaggtac tacgtgcccc aaggagagtg ctgccagtg 1620
tgtgaagatc cagtgtatcc ttttaataat cccgctggct gctatgccaa tggcctgac 1680
cttggcccac gagaccggtg gcgggaagac gactgcacat tctgccagtg cgtcaacggt 1740
gaacgccact gcgttgcgac cgtctgcgga cagacctgca caaacctgt gaaagtgcct 1800
ggggagtggt gccctgtgtg cgaagaacca accatcatca cagttgatcc acctgcatgt 1860
ggggagttat caaactgcac tctgacacgg aaggactgca ttaatggttt caaacgcgat 1920
cacaatggtt gtccgacctg tcagtgcata aacacccagg aactatgttc agaacgtaaa 1980
caaggctgca ccttgaactg tccctcggt ttccctactg atgccaaaaa ctgtgagatc 2040
tgtgagtgcc gccaaggccc caagaagtgc agaccataa tctgtgacaa gtattgtcca 2100
cttggtatgc tgaagaataa gcacggctgt gacatctgtc gctgtaagaa atgtccagag 2160
ctctcatgca gtaagatctg cccctgggt ttccagcagg acagtcacgg ctgtcttatc 2220
tgcaagtgca gagaggcctc tgcttcagct gggccaccca tcctgtcggg cacttgtctc 2280
accgtggatg gtcacatca taaaatgag gagagctggc acgatgggtg ccgggaatgc 2340
tactgtctca atggacggga aatgtgtgcc ctgatcacct gcccggtgcc tgcctgtggc 2400
aaccacacca ttaccctgg acagtgtgc ccatcatgtg catatgactt tgtggtgcag 2460
aagccagagc tcagtactcc ctccatttgc cagccccctg gaggagaata ctttgtggaa 2520
ggagaacagt ggaacattga ctctgtact cagtgcacct gccacagcgg acgggtgctg 2580
tgtgagacag aggtgtgccc accgtgtctc tgccagaacc cctcacgcac ccaggattcc 2640
tgctgccac agtgtacaga tcaacctttt cggccttcct tgtcccga taacagcgt 2700
cctaattact gcaaaaatga tgaaggggat atattcctgg cagctgagtc ctggaagcct 2760
gacgtttgta ccagctgcat ctgcattgat agcgtaatga gctgtttctc tgagtcctgc 2820
ccttctgtat cctgtgaaag acctgtcttg agaaaaggcc agtgtgtgcc ctactgcata 2880
aaagacacaa ttccaaaagaa ggtggtgtgc cacttcagtg ggaaggccta tgccgacgag 2940
gagcgggtggg accttgacag ctgcacccac tgctactgccc tgcagggcca gaccctctgc 3000
tcgaccgtca gctgcccccc tctgccctgt gttgagccca tcaacgtgga aggaagtgc 3060
tgcccaatgt gtccagaaat gtatgtccca gaaccaacca atatacccat tgagaagaca 3120
aaccatcgag gagaggttga cctggaggtt cccctgtggc ccacgcctag tgaaaaatga 3180
atcgtccatc tccctagaga tatgggtcac ctccaggtag attacagaga taacaggctg 3240

```

5 caccgaagtg aagattcttc actggactcc attgcctcag ttgtggttcc cataattata 3300  
 tgccctctcta ttataatagc attcctattc atcaatcaga agaacacagt gataccactg 3360  
 ctttgctggt atcgaacacc aactaagcct tcttccttaa ataactcagct agtatctgtg 3420  
 gactgcaaga aaggaaccag agtccaggtg gacagttccc agagaatgct aagaattgca 3480  
 gaaccagatg caagattcag tggcttctac agcatgcaaa aacagaacca tctacaggca 3540  
 gacaatttct accaaacagt gtgaagaaag gcaactagga tgaggtttca aaagacggaa 3600  
 gacgactaaa tctgctctaa aaagtaaaact agaatttgtg cacttgctta gtggattgta 3660  
 ttggattgtg acttgatgta cagcgctaag accttactgg gatgggctct gtctacagca 3720  
 atgtgcagaa caagcattcc cacttttccct caagataact gaccaagtgt tttcttagaa 3780  
 10 ccaaagtttt taaagtgtct aagatatatt tgccgtgaag atagctgtag agatatattg 3840  
 ggtggggaca gtgagtttg atgggaaag ggggtggagg gtggtgttg gaagaaaaat 3900  
 tggtcagctt ggctcgggga gaaacctgtt aacataaaag cagttcagtg gcccagagg 3960  
 tattttttct ctattgctct gaagactgca ctggttgctg caaagctcag gcctgaatga 4020  
 gcgagaaaca aaaaaggcct tgcgcccag ctgccataac caccttagaa ctaccaggag 4080  
 agcacatcag aacctttga cagccatccc aggtctaaag ccacaagttt cttttctata 4140  
 15 cagtacacac tgcagtaggc agtgaggaaag ccagagaaat gcgtagcgg catttctcta 4200  
 aagcgggtta ttaaggatat atacagttac actttttgct gcttttattt tcttccaagc 4260  
 caatcaatca gccagttcct agcagagtca gcacatgaac aagatctaag tcatttcttg 4320  
 atgtgagcac tggagctttt tttttttaca acgtgacagg aagaggagg agagggtgac 4380  
 gaaccaccag catttccagg ggctatatatt cactgtttgt tgttgctttg ttctgttata 4440  
 ttggttggtt ttcatagttt ttgttgaag tctagcttaa gaagaaactt tttttaaaa 4500  
 20 gactgttttg ggatttctt tcttattat atactgattc tacaaaaatg aaactacttc 4560  
 attttaattg tatattattc aagcaccttt gttgaagctc aaaaaaaatg atgcctcttt 4620  
 aaacttttagc aattatagga gtatttatgt aactatctta tgcttcaaaa aacaaaagta 4680  
 tttgtgtgca tgtgtatata atatatatat atacatatat atttatacac atacaattta 4740  
 tgttttctct tgaatgtat ttttatgca ttttaaccag aacaaaggca gataaacagg 4800  
 cattccatag cagtgccttt gatcacttac aaattttttg aataacacaa aatctcattc 4860  
 25 tacctgcagt ttaattggaa agatgtgtgt gtgagagtat gtatgtgtgt gtgtgtgtgt 4920  
 gtgtgtgcgc gcgcacgcac gccttgagca gtcagcattg cacctgctat ggagaagggt 4980  
 attcctttat taaaatcttc ctatttggga tttgctttca gttggttttc aatttgccta 5040  
 ctggccagag acattgatgg cagttcttat ctgcatcact aatcagctcc tggatttttt 5100  
 tttttttttt tcaacaatg gtttgaaaca actactggaa tattgtccac aataagctgg 5160  
 aagtttgggt tagtatgcct caaatataac tgactgtata ctatagtgtt aacttttcaa 5220  
 30 acagccctta gcacttttat actaattaac ccatttgtgc attgagtttt cttttaaaaa 5280  
 tgcttgttgt gaaagacaca gatacccagt atgcttaacg tgaaaagaaa atgtgttctg 5340  
 ttttgtaaag gaactttcaa gtattgttgt aaataacttg acagagggtg ctgaacttta 5400  
 aaaaaaatta atttattatt ataattgacct aatttattaa tctgaagatt aaccattttt 5460  
 ttgtcttaga atatcaaaaa gaaaaagaaa aaggtgttct agctgtttgc atcaaaggaa 5520  
 aaaaagattt attatcaagg ggcaatattt ttatcttttc caaaataaat ttgttaatga 5580  
 35 tacattacaa aaatagattg acatcagcct gattagtata aattttgttg gtaattaatc 5640  
 cattcctggc ataaaaagtc tttatcaaaa aaaattgtag atgcttgctt tttgtttttt 5700  
 caatcatggc catattatga aaatactaac aggatatagg acaagggtga aattttttta 5760  
 ttattatttt aaagatatga tttatcctga gtgctgtatc tattactctt ttactttggt 5820  
 tctctgttgt ctcttgtaa agaaaaatat aatttctctga agaataaaat agatatatgg 5880  
 cacttggagt gcacatagtt tctacagttt gtttttgggt tcttcaaaaa agctgtaaga 5940  
 40 gaattatctg caacttgatt cttggcagga aataaacatt ttgagttgaa atcaaaaaaa 6000  
 aaaaaaaa a

<210> 34a  
 <211> 1036  
 <212> DNA  
 <213> Human  
  
 <400> 34a

50 mylvagdrgl agcghllvsl lgllllpars gtralvclpc deskceepn rpgsivqgvc 60  
 gccytcasqg nescggtfgi ygtcdrglrc virpplngds lteyeagvce denwtddqll 120  
 gfkpcnenli agcniingkc eentirtcsn pfefpsqdmc lsalkrieee kpdcskarce 180  
 vqf sprcped svliegyapp geccp lpsrc vcnpagclrk vcqpgnl nil vskasgkpg 240  
 ccdlyeckpv fgvdcrtvec ptvqqtacpp dsyetqvrll adgcctlp tr ceclsgl cgf 300  
 pvcevgstpr ivsrgdgtpg kccdvfecvn dtkpacvfnn veyydgd mfr mdncrfrcr 360  
 55 ggvaicftaq cgeinceryy vpegeccpvc edpvy pfnnp agcyanglil ahgdrwredd 420  
 ctfcqcvnge rhcvtatvcgq tctnrvkvpg eccpvcept iitvdppacg elsnc tlrk 480  
 dcingfkrdh ngcrtqc cin tqelcserkq gctln cpfgf ltda qnceic ecrprpkkr 540

EP 1 166 798 A1

piicdkycpl gllknkhgcd icrckkcpel scskicplgf qqdshgclie kreasasag 600  
 ppilsgtclt vdghhkhknee swhdgcrecy clngremcal itcpvpacgn ptihpgqccp 660  
 scaddfvvqk pelstpsich apggeyfvieg etwnidsctq ctchsgrvlc etevcppllc 720  
 5 qnpsrtqdsc cpqctdqpfr pslsrnnsvp nyckndegdi flaaeswkp d vctscicids 780  
 viscfesecp svscerpvlr kgqccpycik dtipkkvvch fsgkayadee rwdldscthc 840  
 yclqggtlcs tvscppplcv epinvegsc p mcpemyvpe ptnipiekt n hrgevdlevp 900  
 lwptpsendi vhlprdmghl qvdyrdnrh psedssldsi asvvvpiiic lsiiiaflfi 960  
 nqkkqwipll cwyrtptkps slnnqlvsvd ckkqtrvqv d ssqrmlriae pdarfsgfys 1020  
 mqkqnhlqad nfyqtv  
  
 10 <210> 35  
 <211> 716  
 <212> DNA  
 <213> Human  
  
 15 <400> 35  
  
 gcagtacctg gagggtcctg cagggggaaa gcgaaccggg ccctgaagtc cggggcagtc 60  
 acccggggct cctgggcccgc tctgccgggc tggggctgag cagcgatcct gctttgtccc 120  
 20 agaagtcagg agggatcagc ccagaaacac accctcctcc ccgggacgcc gcagctttct 180  
 ggaggctgag gaaggcatga agagtgggct ccacctgtcg gccgactgag aaaagaattt 240  
 ccagaactcg gtcctatattt acagattgag aaactatggt tcaagaagag aggacggggc 300  
 ttgagggaat ctccctgattc tccttatatg acctcaaaact gaccatacta aacagtgtag 360  
 aagggtctttt taaggctcta aatgtcaggg tctcccatcc cctgatgcct gacttgtaca 420  
 gtacagtgtg agtagacggg ttcctccacc cagggttgac tcagggggat gatctgggct 480  
 25 ccattctggt ctttaagccc caaacaaggg ttttttcagc tccaggatct ggagcctcta 540  
 tctggttagt gtcgtaacct ctgtgtgcct cccgttacct catctgtcca gtgagctcag 600  
 ccccatccca cctaacaggg tggccacagg gattactgag ggtaagacc ttagaactgg 660  
 gtctagcacc cgataagagc tcaataaatg ttgttccttt ccacatcaaa aaaaaa  
  
 <210> 36  
 <211> 395  
 30 <212> DNA  
 <213> Human  
  
 <400> 36  
  
 ccaataacttc attcttcatt ggtggagaag attgtagact tctaagcatt ttccaaataa 60  
 35 aaaagctatg atttgatttc caacttttaa acattgcatg tcctttgcca tttactacat 120  
 tctccaaaaa aaccttgaaa tgaagaaggc cacccttaaa atacttcaga ggctgaaaat 180  
 atgattatta cattggaatc cttagccta tgtgatattt cttaacttt gcactttcac 240  
 gccagtaaaa accaaagtca gggttaacaa tgcatttta caaatgtta aaacccta 300  
 tgcagttcct tttttaaat attttaaga ttacttaaca acattagaca gtgcaaaaaa 360  
 40 agaagcaagg aaagcattct taattctacc atcct  
  
 <210> 37  
 <211> 134  
 <212> DNA  
 <213> Human  
  
 45 <400> 37  
  
 ccctcgagcg gccgcccggg caggtaacttt taccaccgaa ttgttcactt gactttaaga 60  
 aaccataaaa gctgcctggc tttcagcaac aggctatca acaccatgtt gactctccat 120  
 aaggacacc gtgt  
  
 50 <210> 38  
 <211> 644  
 <212> DNA  
 <213> Human  
  
 <400> 38  
  
 55 aagcctgttg tcatggggga ggtggtggcg cttggtggcc actggcggcc gaggtagagg 60

EP 1 166 798 A1

5  
cagtggcgct tgaattggtc gggggcagcg gcagatttga ggcttaagca acttcttccg 120  
gggaagagtg ccagtgcagc cactgtttaca attcaagatc ttgatctata tccatagatt 180  
ggaatattgg tgggccagca atcctcagac gcctcactta ggacaaatga ggaaactgag 240  
gcttggtgaa gttacgaaac ttgtccaaaa tcacacaact tgtaaaggcg acagccaaga 300  
ttcagagcca ggctgtaaaa attaaaatga acaaattacg gcaaagtttt aggagaaaga 360  
aggatgttta tgttccagag gccagtcgtc cacatcagtg gcagacagat gaagaaggcg 420  
ttcgcaccgg aaaatgtagc ttcccgggta agtaccttgg ccatgtagaa gttgatgaat 480  
caagaggaat gcacatctgt gaagatgctg taaaaagatt gaaagctgaa aggaagtctt 540  
tcaaaggctt ctttggaaaa actggaaaga aagcagttaa agcagtttct gtgggtctaa 600  
10 gcagatggac tcagaggttg tggatgaaaa actaaggacc tcat

<210> 39  
<211> 657  
<212> DNA  
<213> Human

15  
<400> 39

20  
ctttttgttt gggttttcca atgtagatgt ctcagtgaat tgtgcagata tactttgttc 60  
cttatatggt caccagtgtt aattatggac aaatacatta aaacaagggt tcctggccca 120  
gcctcccatc taatctcttt gatactcttg gaatctaagt ctgaggagcg atttctgaat 180  
tagccagtgt tgtaccaact ttctgttagg aattgtatta gaataacctt tctttttcag 240  
acctgctcag tgagacatct tggggaatga agtaggaaaa tagacatttg gtggaaaaac 300  
agcaaaatga gaacattaaa aagactcatt caagtatgag tataaaggcg atggaaattc 360  
tggtccctttg agcaaaatga gaagaaaaaa ttctgctcag cagtattcac tgtgttaaga 420  
ttttttgttt ttacacgaa tggaaaaatg atgtgtaagt ggtatagatt ttaatcagct 480  
aacagtcact ccagagattt tgatcagcac caattcctat agtagtaagt atttaaaagt 540  
25 taagaataac tactacattt aacattataa agtagagttc tggacataac tgaaaattag 600  
atgtttgctt caatagaaat ttgttcccac ttgtattttc aacaaaatta tcggaac

<210> 40  
<211> 1328  
<212> DNA  
<213> Human

30  
<400> 40

35  
acaatttttaa aataactagc aattaatcac agcatatcag gaaaaagtag acagtgaagt 60  
ctgggttagtt tttgtaggct cattatggtt aggggtcgta agatgtatat aagaacctac 120  
ctatcatgct gtatgtatca ctcatcccat ttctatgttc catgcatact cgggcatcat 180  
gctaataatgt atccttttaa gcactctcaa ggaacaaaaa gggcctttta tttttataaa 240  
ggtaaaaaaa attccccaaa tttttgcac tgaatgtacc aaagggtgaag ggacattaca 300  
atatgactaa cagcaactcc atcacttgag aagtataata gaaaatagct tctaaatcaa 360  
acttccttca cagtgccgtg tctaccacta caaggactgt gcactctaagt aataattttt 420  
taagattcac tatatgtgat agtatgatat gcattttatt aaaatgcatt agactctctt 480  
40 ccatccatca aatactttac aggatggcat ttaatacaga ttttctgtat ttccccact 540  
gctttttatt tgtacagcat cattaaacac taagctcagt taaggagcca tcagcaaacac 600  
tgaagagatc agtagtaaga attccatttt ccctcatcag tgaagacacc acaaattgaa 660  
actcagaact atatttctaa gcctgcattt tcaactgatc ataattttct tagtaatat 720  
aagagacagt ttttctatgg catctccaaa actgcatgac atcactagtc ttacttctgc 780  
ttaattttat gagaaggat tcttcatttt aattgctttt gggattactc cacatctttg 840  
45 tttatttctt gactaatcag attttcaata gagtgaagtt aaattggggg tcataaaagc 900  
attggattga catatggttt gccagcctat ggggtttacag gcattgcccc aacatttctt 960  
tgagatctat atttataagc agccatggaa ttcttattat gggatgttgg caatcttaca 1020  
ttttatagag gtcatatgca tagttttcat aggtgttttg taagaactga ttgctctcct 1080  
gtgagttaag ctatgtttac tactgggacc ctcaagagga ataccactta tgttacactc 1140  
ctgcactaaa ggcacgtact gcagtggtgaa gaaatgttct gaaaaagggt tatagaaatc 1200  
50 tggaaataag aaaggaagag ctctctgtat tctataattg gaagagaaaa aaagaaaaac 1260  
ttttaactgg aaatgttagt ttgtacttat tgatcatgaa tacaagtata ttttaattt 1320  
tgaaaaaa

<210> 41  
<211> 987  
<212> DNA  
<213> Human

55

&lt;400&gt; 41

5 aacagagact ggcacaggac ctcttcattg caggaagatg gtagtgtagg caggtaacat 60  
 tgagctcttt tcaaaaaagg agagctcttc ttcaagataa ggaagtggta gttatgggtg 120  
 taacccccgg ctatcagtcg ggatgggtgc caccctcctt gctgtaggat ggaagcagcc 180  
 atggagtggg agggaggcgc aataagacac ccctccacag agcttggcat catgggaagc 240  
 tggttctacc tcttctctgg tcctttgttt aaaggcctgg ctgggagcct tccttttggg 300  
 tgtctttctc ttctccaacc aacagaaaag actgctcttc aaagtgtagg ggtcttcattg 360  
 aaacacagct gccaggagcc caggcacagg gctgggggcc tggaaaaagg agggcacaca 420  
 10 ggaggaggga ggagctggtg ggagatgct ggctttacct aaggtctcga aacaaggagg 480  
 gcagaatagg cagaggcctc tcctgcccag gccctttttt gacagatggc gggacggaaa 540  
 tgcaatagac cagcctgcaa gaaagacatg tgttttgatg acaggcagtg tggccgggtg 600  
 gaacaagcac aggccttggg atccaatgga ctgaatcaga accctaggcc tgccatctgt 660  
 cagccgggtg acctgggtca attttagcct ctaaaagcct cagtctcctt atctgcaaaa 720  
 tgaggcttgt gatacctgtt ttgaagggtt gctgagaaaa ttaagataa gggatccaa 780  
 15 aatagctctac ggccatacca cctgaacgt gcctaacttc gtaagctaa cagggtcagg 840  
 cctggttagt acctggatgg ggagagtatg gaaaacatac ctgcccgcag ttggagtgg 900  
 actctgtctt aacagtagcg tggcacacag aaggcactca gtaataactt gttgaataaa 960  
 tgaagtagcg atttggtgtg aaaaaaa

&lt;210&gt; 42

&lt;211&gt; 956

&lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 42

25 cggacggtgg ggcggacgcg tgggtgcagg agcagggcgg ctgcccactg ccccaaccaa 60  
 ggaaggagcc cctgagtcgg cctgcgcctc catccatctg tccggccaga gccggcatcc 120  
 ttgcctgtct aaagccttaa ctaagactcc cgccccgggc tggccctgtg cagaccttac 180  
 tcagggggatg tttacctggt gctcgggaag ggaggggaa gggccgggga gggggcacgg 240  
 caggcgtgtg gcagccacac gcaggcggcc agggcggcca gggacccaa gcaggatgac 300  
 cacgcacctc cagccactg cctccccga atgcatttgg aaccaaagtc taaactgagc 360  
 30 tcgcagcccc cgcgccctcc ctccgcctcc catcccgctt agcgtctgtg acagatggac 420  
 gcaggccctg tccagccccc agtgcgctcg ttccggctcc cacagactgc cccagccaa 480  
 gagattgctg gaaaccaagt caggccaggt gggcggacaa aagggccagg tgcgacctgg 540  
 ggggaacgga tgctccgagg actggactgt ttttttcaca catcgttgcc gcagcgggtg 600  
 gaaggaaagg cagatgtaaa tgatgtgttg gtttacagg tatattttt ataccttcaa 660  
 tgaattaatt cagatgtttt acgcaaggaa ggacttacc agtattact ctgctgtgct 720  
 35 tttgatctct gcttaccgtt caagagcggt gtgcaggccg acagtcggtg accccatcac 780  
 tcgcaggacc aagggggcgg ggactgctgg ctacgcctcc gctgtgtcct ccctcccctc 840  
 ccttccttgg gcagaatgaa ttcgatgcgt attctgtggc cgccatctgc gcagggtggt 900  
 ggtattctgt catttacaca cgtcgttcta attaaaaagc gaattatact ccaaaa

&lt;210&gt; 43

&lt;211&gt; 536

&lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 43

45 aaataaacac ttccataaca ttttgttttc gaagtctatt aatgcaatcc cacttttttc 60  
 cccctagttt ctaaatgtta aagagagggg aaaaaaggct caggatagtt ttcacctcac 120  
 agtgttagct gtcttttatt ttactcttgg aaatagagac tccattaggg ttttgacatt 180  
 ttgggaaccc agttttacca ttgtgtcagt aaaacaataa gatagtttga gagcatatga 240  
 tctaaataaa gacatttgaa ggggttagttt gaattctaaa agtaggtaat agccaaatag 300  
 cattctcatc ccttaacaga caaaaactta ttgtcaaaa gaattagaaa aggtgaaaat 360  
 attttttcca gatgaaactt gtgccacttc caattgacta atgaaatata aggagacaga 420  
 50 ctggaaaaag tgggttatgc cactttttaa accctttctg gtaaatatta tggtagctaa 480  
 aggggtggtt ccccggcacc tggacctgga caggtagggt tccgtggtta accagt

&lt;210&gt; 44

&lt;211&gt; 1630

&lt;212&gt; DNA

&lt;213&gt; Human

EP 1 166 798 A1

<400> 44

5 ggggagggac gagtatggaa ccctgaaggt agcaagtcca ggcactggcc tgaccatccg 60  
gctccctggg caccaagtcc caggcaggag cagctgtttt ccatcccttc ccagacaagc 120  
tctattttta tcacaatgac ctcttagagag gtctcccagg ccagctcaag gtgtccact 180  
atcccctctg gaggaagag gcaggaaaat tctccccggg tccctgtcat gctactttct 240  
ccatcccagt tcagactgtc caggacatct tatctgcagc cataagagaa ttataaggca 300  
gtgatttccc ttaggcccag gacttgggcc tccagctcat ctgttccttc tggggccatt 360  
catggcagggt tctgggctca aagctgaact ggggagagaa gagatacaga gctaccatgt 420  
10 gactttacct gattgccctc agtttggggt tgcttatagg gaaagagaga gacaaagagt 480  
tacttgttac gggaaatatg aaaagcatgg ccaggatgca tagaggagat tctagcaggg 540  
gacaggattg gctcagatga cccctgaggg ctcttccagt cttgaaatgc attccatgat 600  
attaggaagt cgggggtggg tgggtggtgg gggctagtgg ggtttgaatt taggggcca 660  
tgagcttggg tacgtgagca ggggtgttaag ttagggtctg cctgtatttc tgggtcccctt 720  
ggaaatgtcc ccttcttcag tgctcagacct cagtcccagt gtccatatcg tgcccagaaa 780  
15 agtagacatt atcctgcccc atcccctccc cagtgcactc tgacctagct agtgccctgg 840  
gcccagtgac ctgggggagc ctgggtgcag gccctcactg gttccctaaa ccttgggtgg 900  
tgtgattcag gtcccagggt gggactcagg gaggaatatg gctgagttct gtagtttcca 960  
gagttggctg gtagagcctt cttagaggttc agaatatagg cttcaggatc agctgggggt 1020  
atggaattgg ctgaggatca aacgtatgta ggtgaaagga taccaggatg ttgctaaagg 1080  
tgagggacag tttgggtttg ggacttacca ggggtgatgt agatctggaa ccccaagt 1140  
20 aggtcggagg gagttaaggt cagtatggaa gatagggttg ggacagggtg ctttggaaatg 1200  
aaagagtgac cttagagggt tccttggggc tcagggaatgc tcctgctgct gtgaagatga 1260  
gaagggtgct ttaactcagtt aatgatgagt gactatatat accaaagccc ctacctgctg 1320  
ctgggtccct tgtagcacag gagactgggg ctaaggggccc ctcccaggga agggacacca 1380  
tcaggcctct ggctgaggca gtagcataga ggatccattt ctacctgcat ttcccaggag 1440  
actagcagga ggcagccttg agaaaacggc agttcccagg ccagcgctctg gctgttctct 1500  
25 cattgtcact gccctctccc caacctctcc tctaaccac tagagattgc ctgtgtcctg 1560  
cctcttgctt cttgtagaat gcagctctgg ccctcaataa atgcttccctg cattcatctg 1620  
caaaaaaaaa

<210> 45

<211> 169

<212> DNA

<213> Human

<400> 45

35 tcttttgcct ttagcttttt atttttgtat taacaggagt cttattacac ataggtctga 60  
taaaactggg ttatgatctt cagtctgatt ccagtctgctc ataactagat aacgtatgaa 120  
ggaaaaacga cgacgaacaa aaaagtaagt gcttgggaaga cttagtgtga

<210> 46

<211> 769

<212> DNA

<213> Human

<400> 46

45 tgcaggctcat atttactatc ggcaataaaa ggaagcaaa gtagtattaag cagcgggtgga 60  
atttgcctgct ttcaactttt ataaagtgtc acataaaatg tcatatttcc aaatttaaaa 120  
acataactcc agttcttacc atgagaacag catggtgatc acgaaggatc ttcttgaaaa 180  
aaacaaaaac aaaaacaaaa aacaatgatc tcttctgggt atcacatcaa atgagataca 240  
aagggtgtact aggcaatctt agagatctgg caacttattt tatatataag gcatctgtga 300  
ccaagagacg ttatgaatta aatgtacaaa tgtattatgt ataaatgtat taaatgcaag 360  
cttcatataa tgacaccaat gtctctaagt tgctcagaga tcttgactgg ctgtggccct 420  
ggccagctcc tttcctgata gtctgattct gccttcatat ataggcagct cctgatcatc 480  
catgccagtg aatgagaaaa caagcatgga atataataac tttaacatta aaaaatgttt 540  
50 tattttgtaa taaaatcaaa tttccattg aaaccttcaa aaactttgca gaatgaggtt 600  
ttgatataat tgtacaagta gtaccttctt agtgcaagaa aacatcatta tttctgtctg 660  
cctgcctttt tgtttttaaa aatgaagact atcattgaaa caagtttgtc ttcagtatca 720  
ggacatgttg acggagagga aaggtaggaa agggttaggg atagaagcc

<210> 47

<211> 2529

<212> DNA



EP 1 166 798 A1

<213> Human

<400> 47

5	tttagttcat	agtaatgtaa	aaccatttgt	ttaattctaa	atcaaatac	tttcacaaca	60
	gtgaaaatta	gtgactgggt	aagggtgtgc	actgtacata	tcatcatttt	ctgactgggg	120
	tcaggacctg	gtcctagtcc	acaagggtgg	caggaggagg	gtggagggcta	agaacacaga	180
	aaacacacaa	aagaaaaggaa	agctgccttg	gcagaaggat	gaggtgggtga	gcttgccgag	240
	ggatgggtggg	aaggggggctc	cctgttgggg	ccgagccagg	agtcccaagt	cagctctcct	300
10	gccttactta	gctcctggca	gaggggtgagt	ggggacctac	gaggttcaaa	atcaaatggc	360
	atttggccag	cctggcttta	ctaacaggtt	cccagagtgc	ctctgttggc	tgagctctcc	420
	tgggctcact	ccatttcatt	gaagagtcca	aatgattcat	tttctacc	acaacttttc	480
	attattcttc	tggaaaccca	tttctgttga	gtccatctga	cttaagtcct	ctctccctcc	540
	actagtggg	gccactgcac	tgaggggggt	cccaccaatt	ctctctagag	aagagacact	600
	ccagaggccc	ctgcaacttt	gcggatttcc	agaagggtgat	aaaaagagca	ctcttgagt	660
15	ggtgcccagg	aatgtttaaa	actatcagg	cacactataa	agctgggtgt	ttcttcctgt	720
	caagtggatt	cggcatatga	accacctact	caatacttta	tattttgtct	gtttaaacac	780
	tgaactctgg	tgttgacagg	tacaaaggag	aagagatggg	gactgtgaag	aggggagggc	840
	ttccctcatc	ttctcaaga	tctttgttcc	cataaactat	gcagtcataa	ttgagaaaaa	900
	gcaatagatg	gggcttccca	ccatttgttg	gttattgctg	gggttagcca	ggagcagtgt	960
	ggatggcaaa	gtaggagaga	ggcccagagg	aaagcccatc	tccctccagc	tttgggttct	1020
20	ccagaaagag	gctggatttc	tgggatgaag	cctagaaggc	agagcaagaa	ctgttccacc	1080
	aggtgaacag	tcctacctgc	ttgggtaccat	agtcctcaa	taagattcag	aggaagaagc	1140
	ttatgaaact	gaaaatcaaa	tcaaggtatt	gggaagaata	atttccctc	gattccacag	1200
	gaggggaagac	cacacaatat	cattgtgctg	gggtcccca	aggccctgcc	acctggcttt	1260
	acaaatcatc	aggggttgcc	tgcttgccag	tcacatgctt	ccctggtttt	agcacacata	1320
	caaggagttt	tcagggaact	ctatcaagcc	atacaaaat	cagggtcaca	tgtgggtttc	1380
25	ccctttccct	gcctcttcat	aaaagacaac	ttggcttctg	aggatgggtg	tcttttgcac	1440
	gcagttgggc	tgacctgaca	aagccccag	tttctgttgg	caggttcttg	gagaggatgc	1500
	attcaagctt	ctgcagccta	ggggacaggg	ctgcttgttc	agttattact	gcctcggagc	1560
	tccaaatccc	accaaagtcc	tgactccagg	tctttcctaa	tgacacagtag	tcagtctcag	1620
	cttcggcagt	attctcggct	gtatgttctc	tggcagagag	aggcagatga	acatagtttt	1680
	agggagaaa	ctgatgggaa	acctgtgagt	taagccacat	gtctcaccag	gaataattta	1740
30	tgccaggaaa	ccagggaagtc	attcaagtgt	ttctctgagg	ccaaagacac	tgagcacagc	1800
	ccagagccaa	taaaagatct	ttgagtctct	ggtgaattca	cgaagtgacc	ccagctttag	1860
	ctactgcaat	tatgattttt	atgggacagc	aatttcttgc	atctctacag	aggaagaaga	1920
	gggggagtgg	gaggggaagg	aaagagaaca	gagcggcact	gggatttgaa	aggggaacct	1980
	ctctatctga	ggagccccc	ctggcttcag	aagcaactta	ccaaggggta	tttaaagaca	2040
	tgaatttcc	cagaaatacc	atttgggtgca	tccctttgtt	tctgtaatat	taaaactcagg	2100
35	tgaaattata	ctctgacagt	ttctctcttc	ctgctcttcc	cctctgcaga	gtcaggacct	2160
	gcagaactgg	ctgaacaag	atttcatggt	gtcaccatg	agagatgact	caatgccaa	2220
	gcctgaagtt	atagagtgtt	tacagcgtg	gcgatattca	ggggtcatcg	ccaactggtc	2280
	tcgagttcca	aagctctgat	gaagaacaa	gactccttga	tgtgttactg	atcccaactga	2340
	ttccaggagt	caagattagc	caggaagcca	aacaccagga	gttgggggtg	cacgtcacca	2400
	gtccagagcc	ctgccacgga	tgtacgcagg	agcccagcat	taggcaatca	ggagccagaa	2460
40	catgatcacc	agggccacaa	ataggaagag	gcgtgacagg	aactgctcgt	ccacatacct	2520
	gggtgttcc						

<210> 48

<211> 1553

<212> DNA

<213> Human

<400> 48

50	tttttttttt	tttttgattt	ctgggacaat	taagctttat	ttttcatata	tatatatatt	60
	ttcatatata	tatatacata	catatataaa	ggaacaatt	tgcaaattha	cacacctgac	120
	aaaaccatat	atacacacat	atgtatgcat	acacacagac	agacacacac	acccgaagct	180
	ctagccaggc	ccgtttttcca	tccctaagta	ccattctctc	atttggggcc	ttctagggtt	240
	ggggccctga	gcttggtttg	tagaagtgtg	gtgctaatat	aaccatagct	ttaatcccca	300
	tgaaggacag	tgtagacctc	atctttgtct	gtcccccgtc	gcctttcagt	tttactgtat	360
	ccatcaagag	ggctatggga	gccaagtga	cacgggggat	tgaggcta	tcacctgaac	420
	tcgaaaacag	gcgccagctt	cctcaccgca	ggcacgcgtc	ttttcttttt	ttttctcga	480
	gacggagtct	cgctgtgttg	cccaggctgg	agtgcagtgg	cacggtctcg	gctcactgca	540
55	agctccacct	cctggattca	taccattctc	ctgcttcagc	cttccgagta	gctgggacta	600
	taggtgccaa	ccactacgcc	tagctaattt	ttttttgtat	ttttagtaga	gacagggttt	660

EP 1 166 798 A1

5 caccgtgtta gccaggatgg tctcgtcctg acttttgtgat ccgcccgcct cggcctccca 720  
 aagtgtctggg attacaggcg tgagccacca cacctggccc cggcacgtat cttttaagga 780  
 atgacaccag ttcctggctt ctgaccaaag aaaaaatgtc acaggagact ttgaagaggc 840  
 agacaggagg gtggtggcag caacactgca gctgcttctg gatgctgctg ggggtgctctc 900  
 cggagcgggt gtgaacagcg cacttcaaca tgagcaggcg cctggctccg gtgtgtcctc 960  
 acttcagtgg tgcacctgga tgggtggaagc cagcctttgg ggcaggaaac cagctcagag 1020  
 aggtaccca gctcagctgc tggcaggagc caggtattta cagccataat gtgtgtaaag 1080  
 aaaaaacacg ttctgcaaga aactctccta cccgctcggg agactggggc tccttgcttg 1140  
 10 ggatgagctt cactcaacgt ggagatgggt gtggactggg ccctgaaaag cgggccttgc 1200  
 agggccaagt gaggtcctca . ggtcctaac ccagtggccc tctgaaaggg ggtgtgcagg 1260  
 cgaggggagc agggagcttc tctctagtcc ctttgagggc tttggctgag agaagagtga 1320  
 gcagggagct gggaatggct caggcaggga agggagctga agtgattcgg ggctaatagcc 1380  
 tcagatcgat gtatttctct ccctggctct ccggagccct cttgtcaccg ctgctgccct 1440  
 gcagggaggc catctcttct gggagcttat ctgacttaac ttcaactaca agttcgctct 1500  
 tacgagaccg ggggtagcgt gatctcctgc ttcctgagc gcctgcacgg cag  
 15 <210> 49  
 <211> 921  
 <212> DNA  
 <213> Human  
 20 <400> 49  
 ctgtggtccc agctactcag gaggctgagg cgggaggatt gcttgagccc aggagtggga 60  
 tggtgcagtg agccaagatc gcaccattgc cctccactct ggccacgga gcaataccct 120  
 gtctcagaaa acaaaacaaca aaaagcagaa acgctgaagg ggtcggttta cgggaaaacc 180  
 25 gcctgtcaga acacttggct actcctaccc cagatcagtg gacctgggaa tgaggggttg 240  
 tcccgggagg cttttctcca agctgttgcc accagaccgg ccatgggaac cctggccaca 300  
 gaagcctccc ggggagtgag ccagagcctg gaccgctgtg ctgatgtgtc tggggtggag 360  
 ggaggggtggg gagtgtgcaa ggggtgtgtg gtgcccgggg ggtgttcatg ggcaagcatg 420  
 tgctgtcctg tgtgtgtgctg tgcccctccc ctgcagccgt cgggtggtatc tcctccagc 480  
 cccttcgcca cctcttgagc attgtctgtc cacgtgagac tgcccagaga cagcagagct 540  
 30 ccacgtgggt ttaaggggag accttccct ggacctgggg gtctcgccgt atctcatgac 600  
 cagggtgctaa atgacccgac atgcatcacc tgcttttcta tgaccaacct ccctgtcccc 660  
 gtcccgtga cctgcccccg tggcgtctca cgggtgatgc tgctcctgac attgggtgtc 720  
 actgtagcaa actacattct ggatgggaat ttctatgtac atgtgtggca tgtggaaaat 780  
 ttcaaataaa atggacttga tttagaaagc caaaaagctg tgtggctcct ccagcacgga 840  
 tactttgacc tcttgcttac aacccttcc ttgggtccga ggctggtagc tttgttact 900  
 tcagatgggt gggggcgggt g  
 35 <210> 50  
 <211> 338  
 <212> DNA  
 <213> Human  
 40 <400> 50  
 atgatctatc tagatgccct accgtaaaat caaaacacaa aaccctactg actcattccc 60  
 tcccttccag atattacccc atttctctac ttccattgt agccaaactt tccaaaaatt 120  
 catgttctgt cttcatttcc tcatgttcaa ccacccctgt cttagctacc acccctcagt 180  
 aacgacctag cctgggtaga aacaaatgtc agcatgatac catactcaat gatccttctg 240  
 45 cactgttgtc attgtcatca ttccatggcc ttactttccc tctcagcgcc atttgctaca 300  
 gtaagaaaact ttctttcttg aattcttgggt tctcttgg  
 <210> 51  
 <211> 1191  
 <212> DNA  
 <213> Human  
 50 <400> 51  
 ctagcaagca ggtaaacgag ctttgtacaa acacacacag accaacaacat ccggggatgg 60  
 ctgtgtgttg ctagagcaga ggctgattaa acactcagtg tgttggctct ctgtgccact 120  
 cctggaaaat aatgaattgg gtaaggaaaca gtttaataaga aaatgtgcct tgctaactgt 180  
 55 gcacattaca acaaagagct ggcagctcct gaaggaaaag ggcttgtgcc gctgccgttc 240  
 aaacttgtca gtcaactcat gccagcagcc tcagcgtctg cctcccagc acaccctcat 300

EP 1 166 798 A1

5      tacatgtgtc tgtctggcct gatctgtgca tctgctcgga gacgctcctg acaagtcggg 360  
       aatttctcta tttctccact ggtgcaaaga gcggatttct ccctgcttct cttctgtcac 420  
       ccccgcctc ctccccagg aggtcctctg atttatggta gctttggact tgcttccccg 480  
       tctgactgtc cttgacttct agaattggaag aagctgagct ggtgaaggga agactccagg 540  
       ccatcacaga taaaagaaaa atacaggaag aaatctcaca gaagcgtctg aaaatagagg 600  
       aagacaaact aaagcaccag catttgaaga aaaaggcctt gagggagaaa tggcttctag 660  
       atggaatcag cagcggaaaa gaacaggaag agatgaagaa gcaaaatcaa caagaccagc 720  
       accagatcca ggttcttagaa caaagtatcc tcaggcttga gaaagagatc caagatcttg 780  
 10      aaaaagctga actgcaaatc tcaacgaagg aagaggccat tttaaagaaa ctaaagtcaa 840  
       ttgagcggac aacagaagac attataagat ctgtgaaagt ggaaagagaa gaaagagcag 900  
       aagagtcaat tgaggacatc tatgctaata tccctgacct tccaaagtcc tacatacctt 960  
       ctaggttaag gaaggagata aatgaagaaa aagaagatga tgaacaaaat aggaaagctt 1020  
       tatatgccat ggaaattaaa gttgaaaaag acttgaagac tggagaaagt acagttctgt 1080  
       cttccaatac ctctggccat cagatgactt taaaagggtac aggagtaaaa gtttaagatg 1140  
       atgggcaaaa gtccagtgtg ttcagtaaaag tgctaatac aagttggagg t  
 15      <210> 52  
       <211> 1200  
       <212> DNA  
       <213> Human  
 20      <400> 52  
       aacagggact ctcaactctat caaccccagg ctggagtcgg gtgcgcccac cctggctccc 60  
       tgcaaacctcc gctctccagg ctcaagcaac tctcctgcct cagtcgctct agtagctggg 120  
       actacaggca cacaccacca tgcccagcca atttttgcat tttttgtaga gacagggttt 180  
       cgccttctgt ccaggccggc atcatatact ttaaatcatg ccagatgac tttaatacct 240  
 25      aatacaatat atcagggttg tttaaaaata attgcttttt tattattttt gcattttttg 300  
       accaacctta atgctatgta aatagtgtt atactgttg ttaacaacag tatgacaatt 360  
       ttggcttttt ctttgtatta ttttgtatt ttttttttta ttgtgtggtc tttttttttt 420  
       ttctcagtg tttcaattcc tccttggttg aatccatgga tgcaaaaccc acagatatga 480  
       agggtcggct atatatgcat tgatgattgt cctattatat tagttataaa gtgtcattta 540  
       atatgtagt aaagtattg tgatgtgaa agagttagtg aaaacataaa catttgacc 600  
 30      tttcaagaaa ggtagcttg tgaagtttt caccttcaa ctatgtccca gtcagggtc 660  
       tgctactaat tagctataat cttgacacaa attacatcac ctttgagtct cagttgcctc 720  
       acctgtaaaa tgaaagaact ggatactctc taaggctact tccagccctg tcattctata 780  
       actctgttat gctgaggaag aaattcacat tgtgttaact gtatgagtc aactgaaaat 840  
       gattattaaa gtgggaaaaa gccaatgtct tctcttagaa agctcaacta aatttgagaa 900  
       gaataatctt ttcaatttt taagaattta aatattttta aggttttgac ctattttatt 960  
 35      agagatggg tctcactctg tcacccagac tggagtacag tggcacaatc atagctcact 1020  
       gctgcctcaa attcatgggc tcaagtgtc ctctgcctc tgccctcaga gtactgcga 1080  
       ctatgggcat gtgccaccac gcctggctaa catttgtatt gacctattta tttattgtga 1140  
       tttatatctt tttttttttt tctttttttt ttttttataa aatcagaaat acttattttg 1200  
 40      <210> 53  
       <211> 989  
       <212> DNA  
       <213> Human  
       <400> 53  
 45      aagccaccac tcaaaacttc ctatacattt tcacagcaga gacaagtga catttatttt 60  
       tatgcctttc ttcttatgtg tatttcaagt ctttttcaaa acaaggcccc aggactctcc 120  
       gattcaatta gtcttgaggc tggctgactg tgcaggagtc caggagcct ctacaaatgc 180  
       agagtgactc tttaccaaca taaaccctag atacatgcaa aaagcaggac ccttccctcca 240  
       ggaatgtgcc atttcagatg cacagcacc atgcagaaaa gctggaattt tccttggac 300  
       cgactgtgat agaggtgctt acatgaacat tgctactgtc tttctttttt tttgagacag 360  
 50      gtttcgcttg tgcccaggct gagtgcattg cgtgatctca ctactgcaa ttccacctcc 420  
       aggttcaagc atttctctgc tcagcctcct agtagctggg ttacaggcac tgccaccatg 480  
       cgggctaatt ttgtatttt gttagatgg atttctccat ttggtcaggc ggtctcgaac 540  
       cccaacctca gtgatctgcc acctcagcct cctaagtggt ggattacagg atgagccacc 600  
       cgaccggcca ctactgtctt tctttgacct ttccagtttc gaagataaag aggaaataat 660  
       ttctctgaag tacttgataa aatttccaaa caaacacat gtccacttca ctgataaaaa 720  
 55      atttacgca gtttggcacc taagagtatg acaacagcaa taaaaagtaa tttcaagag 780  
       ttaagatttc ttcagcaaaa tagatgattc acatcttcaa gtcctttttg aaatcagtta 840  
       ttaatattat tctttcctca tttccatctg aatgactgca gcaatagttt tttttttttt 900

EP 1 166 798 A1

tttttttttt ttgcgagatg gaatctcgct ctgtcgccca gcgggagtgc actggcgcaa 960  
gccccgctca ccgcaatctc tgccaccgc

<210> 54  
<211> 250  
<212> DNA  
<213> Human

<400> 54

catttcccca ttggtcctga tgttgaagat ttagttaaag aggctgtaag tcaggttcga 60  
gcagaggcta ctacaagaag tagggaatca agtccctcac atgggctatt aaaactaggt 120  
agtgttgag tagtgaaaaa gaaatctgag caacttcata acgtaactgc ctttcagggg 180  
aaagggcatt ctttaggaac tgcattctgt aaccacacac ttgatccaag agctagggaa 240  
acttcagttg

<210> 55  
<211> 2270  
<212> DNA  
<213> Human

<400> 55

gcgccccga gcagcgcccg cgccctccgc gccttctccg ccgggacctc gagegaaaga 60  
ggcccgcgcg ccgcccagcc ctgcctccc tgcccaccgg gcacaccgg ccgccacccc 120  
gaccccgctg cgcacggcct gtccgctgca caccagcttg ttggcgtctt cgtcgccggc 180  
ctcgccccgg gctactcctg cgcgccacaa tgagctcccg catcgccagg gcgctcgcc 240  
tagtcgtcac ccttctccac ttgaccaggc tggcgctctc cactgcccc gctgcctgcc 300  
actgccccct ggaggcgccc aagtgcgcgc cgggagtcgg gctggtccgg gacggctggc 360  
gctgctgtaa ggtctgcgcc aagcagctca acgaggactg cagcaaacg cagccctggc 420  
accacaccaa ggggctggaa tgcaacttcg gcgccaagtc caccgctctg aaggggatct 480  
gcagagctca gtcagagggc agaccctgtg aatataactc cagaatctac caaacgggg 540  
aaagtttcca gcccaactgt aaacatcagt gcacatgtat tgatggcgcc gtgggctgca 600  
ttcctctgtg tccccaagaa ctatctctcc ccaacttggg ctgtcccaac cctcggtctg 660  
tcaaatgtac cgggcaagtgc tgcgaggagt ggtctgtgta cgaggatagt atcaaggacc 720  
ccatggaggga ccaggacggc ctcttggaagg agagctggg attcgatgcc tccgaggtgg 780  
agtgtgacgag aaacaatgaa ttgattgcag ttgaaaaagg cagctcactg aagcggtccc 840  
ctgttttttg aatggagcct cgcattctat acaacccttt acaaggccag aaatgtattg 900  
ttcaaaacac ttcatgttcc cagtgtctaa agacctgtgg aactggatc tccacacgag 960  
ttaccaatga caaccctgag tgcgccttg tgaagaaac ccgatttgt gaggtgcggc 1020  
cttgtggaca gccagtgtac agcagcctga aaaagggcaa gaaatgcagc aagaccaaga 1080  
aatcccccgga accagtccagg tttacttacg ctggatgttt gagtgtgaag aaataccggc 1140  
ccaagtactg cggttcctgc gtggacggcc gatgctgcac gccccagctg accaggactg 1200  
tgaagatgcg gttccgctgc gaagatggg agacattttc caagaacgtc atgatgatcc 1260  
agtctgcaa atgcaactac aactgcccgc atgccaatga agcagcggtt cccttctaca 1320  
ggctgttcaa tgacattcac aaatttaggg actaaatgct acctgggttt ccagggcaca 1380  
cctagacaaa caaggagaa gagtgtcaga atcagaatca tggagaaaaat gggcgggggg 1440  
ggtgtgggtg atgggactca ttgtagaaag gaagccttgc tcattcttga ggagcattaa 1500  
ggtatttcga aactgccaag ggtgctgtg cggatggaca ctaatgcagc cagcattgga 1560  
gaataactttg cttcatagta ttggagcaca tgttactgct tcatttttga gcttgtggag 1620  
ttgatgactt tctgttttct gtttgtaaat tatttgcata gcatattttc tctaggcttt 1680  
tttctttttg ggtttctaca gtcgtaaaag agataataag attagtttga cagtttaaaag 1740  
cttttattcg tcctttgaca aaagtaaag ggagggcatt ccattccctc ctgaaggggg 1800  
acactccatg agtgtctgtg agaggcagct atctgcactc taaactgcaa acagaaatca 1860  
ggtgttttaa gactgaatgt tttatttatc aaaatgtagc ttttggggag ggaggggaaa 1920  
tgtaatactg gaataatttg taaatgattt taattttata ttcaagtgaag agattttatt 1980  
tatggaatta accatttaat aaagaaatat ttacctaata tctgagtgtg tgccattcgg 2040  
tatttttaga ggtgctccaa agtcattagg aacaacctag ctcacgtact caattattca 2100  
aacaggactt attgggatac agcagtgaat taagctatta aaataagata atgattgctt 2160  
ttataccttc agtagagaaa agtcttttgc tataaagtaa tgtttaaaaa acatgtattg 2220  
aacacgacat tgtatgaagc acaataaaga ttctgaagct aaaaaaaaaa

<210> 56  
<211> 1636  
<212> DNA  
<213> Human

&lt;400&gt; 56

5 cttgaatgaa gctgacacca agaaccgcgg gaagagcttg ggcccaaagc aggaaaggga 60  
 agcgctcgag ttggaaagga accgctgctg ctggccgaac tcaagcccgg gcgccccac 120  
 cagtttgatt ggaagtccag ctgtgaaacc tggagcgtcg cttctctccc agatggctcc 180  
 tggtttgctt ggtctcaagg acactgcac gtcaaaactga tcccctggcc gttggaggag 240  
 cagttcatcc cttaaagggtt tgaagccaaa agccgaagta gcaaaaatga gacgaaagg 300  
 cggggcagcc caaaagagaa gacgctggac tgtggtcaga ttgtctgggg gctggccttc 360  
 10 agcccggtggc cttccccacc cagcaggaag ctctgggcac gccaccacc ccaagtggcc 420  
 gatgtctctt gcctggttct tgctacggga ctcaacgatg gcagatcaa gatctgggag 480  
 gtgcagacag ggctctctgt tttgaatctt tccggccacc aagatgtcgt gagagatctg 540  
 agcttcacac cactggcag tttgattttg gtctccgctg cacgggataa gactcttcgc 600  
 atctgggacc tgaataaaca cggtaaacag attcaagtgt tatcgggcca cctgcagtgg 660  
 gtttactgct gttccatctc ccagactgc agcatgctgt gctctgcagc tggagagaag 720  
 15 tccgtctttc tatggagcat gaggtcttac acgttaattc ggaagctaga gggccatcaa 780  
 agcagtgttg tctcttgta cttctcccc gactctgcc tgcttgtcac ggcttcttac 840  
 gataccaatg tgattatgtg ggaccctac accggcgaaa ggctgaggtc actccaccac 900  
 acccagggtg accccgccat ggatgacagt gacgtccaca ttagctcact gagatctgtg 960  
 tgcttctctc cagaaggctt gtaccttgcc acggtggcag atgacagact cctcaggatc 1020  
 tgggccctgg aactgaaaac tcccattgca ttgctccta tgaccaatgg gctttgctgc 1080  
 20 acattttttc cacatgggtg agtcattgcc acagggacaa gagatggcca cgtccagttc 1140  
 tggacagctc ctagggtcct gtccctactg aagcacttat gccggaaaagc ccttcgaagt 1200  
 ttcctaacaa cttaccaagt cctagcactg ccaatcccca agaaaatgaa agagtctctc 1260  
 acatacagga ctttttaagc aacaccacat cttgtgcttc tttgtagcag ggtaaatcgt 1320  
 cctgtcaaag ggagttgctg gaataatggg ccaaaccatc ggtcttgcat tgaaatagca 1380  
 tttctttggg attgtgaata gaatgtagca aaaccagatt ccagtgtaca taaaagaatt 1440  
 25 tttttgtctt taaatagata caaatgtcta tcaactttaa tcaagttgta acttatattg 1500  
 aagacaattt gatacataat aaaaaattat gacaatgtcc tgggaaaaaa aaaatgtaga 1560  
 aagatggtga aggggtggat ggatgaggag cgtggcgacg ggggcctgca gcgggttggg 1620  
 gaccctgtgc tgcgtt

&lt;210&gt; 57

&lt;211&gt; 460

&lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 57

35 ccattgtgtg atgagagaga gagagattgg gagggagagg gagctcacta gcgcatatgt 60  
 gcctccaggg ggctgcagat gtgtctgagg gtgagcctgg tgaaagagaa gacaaaagaa 120  
 tggatgagc taaagcagcc gcctgggggtg ggaggccgag cccatttgta tgcagcaggg 180  
 ggcaggagcc cagcaaggga gcctccattc ccaggactct ggaggagct gagaccatcc 240  
 atgcccgag agccctccct cacactccat cctgtccagc cctaattgtg caggtgggga 300  
 aactgaggct gggaagtcac atagcaagtg actggcagag ctgggactgg aaccaacca 360  
 40 gcctcctaga ccacggttct tcccatcaat ggaatgctag agactccagc caggtgggta 420  
 ccgagctcga attcgtaatc atggtcatag ctgtttcctg

&lt;210&gt; 58

&lt;211&gt; 1049

&lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 58

50 atctgatcaa gaatacctgc cctggctcact ctgcggatgt ttctgtccac ttgttcacat 60  
 tgaggaccaa gatatccttt tttacagagg cacttggtcg gtctaacaca gacacctcca 120  
 tgacgacatg ctggctcaca ttttgaggtt ctgcagaagt cccctcccca gcctggacta 180  
 cagcagcact ttcccggtgg ggtgcagtag ccgtttcgac agagcctgga gcactctgaa 240  
 gtcaagtgtc gtgcaggttg taccgtggct ctgcattcct caggcattaa aggtcttttg 300  
 ggatctacaa tttttagtag ttttccattg tgagtctggg tcatactttt actgcttgat 360  
 aaaaatgtaaa cttcacctag ttcattctct ccaaatccca agatgtgacc ggaaaagtag 420  
 cctctacagg acccactagt gccgacacag agtgggtttt cttgccactg ctttgcaca 480  
 ggactttgct ggagagttag gaaattccca ttacgatctc caaacacgta gcttccatac 540  
 55 aatctttctg actggcagcc ccggtataca aatccacca ccaaaggacc attactgaat 600  
 ggcttgaatt ctaaaagtga tggctcactt tcataatctt tcccctttat tatctgtaga 660


attctggctg atgatctgtt ttttccattg gagtctgaac acagtatcgt taaattgatg 720  
 tttatatcag tgggatgtct atccacagca catctgcctg gatcgtggag cccatgagca 780  
 aacacttcgg ggggctggtt ggtgctgttg aagtgtgggt tgctccttgg tatggaataa 840  
 5 ggcacgttgc acatgtctgt gtccacatcc agccgtagca ctgagcctgt gaaatcactt 900  
 aacccatcca tttcttccat atcatccagt gtaatcatcc catcaccaag aatgatgtac 960  
 aaaaaccgt cagggccaaa gagcagttgc cctcccagat gctttctgtg gagttctgca 1020  
 acttcaagaa agactctggc tgttctcaa  
  
 <210> 59  
 10 <211> 747  
 <212> DNA  
 <213> Human  
  
 <400> 59  
 15  
 tttttcaaat cacatatggc ttctttgacc ccatcaaata actttattca cacaaacgtc 60  
 ccttaattta caaagcctca gtcattcata cacattaggg gatccacagt gttcaaggaa 120  
 cttaaatata atgtatcata ccaaccacag taaaccaagt acaaaaaata ttcataataa 180  
 gttgttcaca cgtaggctct agattaccag cttctgtgca aaaaaaggaa atgaagaaaa 240  
 20 atagatttat taactagtat tggaaactaa ctttgtgcct ggcttaaac ctccctcacg 300  
 ctgctctgtc ccacacaaat gtttaagaag tcaactgcaat gtactccccg gctctgatga 360  
 aaagaagccc ctggcacaaa agattccagt gccctgaag aggctccctt cctcctgtgg 420  
 gctctcctag aaaaccagcg ggacggcctc cctgctgata ccgtctataa ccttaggggg 480  
 ccctcgggca ggcaacggca gtggactcat ctcggtgatg gctgtagatg ctaacactgg 540  
 ccaattcaat gccacaccta ctggttacct tttagaggca tttctccaga cagaagcccc 600  
 25 ttgaagccta ggtagggcag gatcagagat acaccctgtt ttgtctcgaa gggctccaca 660  
 gccagtagc acatgcttgc agaagtagta tctctggact tctgcctcca gtcgaccggc 720  
 cggaattta gtagtaatag cggccgc

### Claims

1. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems.
2. Pharmaceutical compositions comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems.
3. Pharmaceutical compositions comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium.
4. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
5. Pharmaceutical compositions comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
6. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems.
7. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as

compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.

8. Pharmaceutical compositions comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.
9. Pharmaceutical compositions according to claims 1-8 which are intended for simultaneous or separate sequential therapeutical application.
10. Pharmaceutical compositions according to claims 1-8 which comprise as compound I at least one of
  - a) compounds which inhibit receptor tyrosine kinase activity,
  - b) compounds which inhibit ligand binding to receptors,
  - c) compounds which inhibit activation of intracellular signal pathways of the receptors,
  - d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
  - e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
  - f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.
11. Pharmaceutical compositions according to claims 1-8 which comprise as compound II at least one of
  - g) compounds which inhibit receptor tyrosine kinase activity,
  - h) compounds which inhibit ligand binding to receptors,
  - i) compounds which inhibit activation of intracellular signal pathways of the receptors,
  - j) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
  - k) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
  - l) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.
12. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.
13. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II Seq. ID Nos. 34a
14. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35 and/ or scFv-tTF conjugate.
15. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one small molecule of general formula I



in which

r

has the meaning of 0 to 2,


n

has the meaning of 0 to 2;

R<sub>3</sub> und R<sub>4</sub>

a) each independently from each other have the meaning of lower alkyl,

b) together form a bridge of general partial formula II,




wherein the binding is via the two terminal C- atoms,

and

m

has the meaning of 0 to 4; or

c) together form a bridge of partial formula III



wherein one or two of the ring members T<sub>1</sub>, T<sub>2</sub>, T<sub>3</sub>, T<sub>4</sub> has the meaning of nitrogen, and each others have the meaning of CH, and the binding is via the atoms T<sub>1</sub> and T<sub>4</sub>;

G

has the meaning of C<sub>1</sub>-C<sub>6</sub>- alkyl, C<sub>2</sub>-C<sub>6</sub>- alkylene or C<sub>2</sub>-C<sub>6</sub>- alkenylene; or C<sub>2</sub>-C<sub>6</sub>- alkylene or C<sub>3</sub>-C<sub>6</sub>-alkenylene, which are substituted with acyloxy or hydroxy; -CH<sub>2</sub>-O-, -CH<sub>2</sub>-S-, -CH<sub>2</sub>-NH-, -CH<sub>2</sub>-O-CH<sub>2</sub>-, -CH<sub>2</sub>-S-CH<sub>2</sub>-, -CH<sub>2</sub>-NH-CH<sub>2</sub>-, oxa (-O-), thia (-S-) or imino (-NH-),


A, B, D, E and T

independently from each other have the meaning of N or CH, with the proviso that not more than three of these Substituents have the meaning of N,




Q has the meaning of lower alkyl, lower alkyloxy or halogene,  
 R<sub>1</sub> and R<sub>2</sub> independently from each other have the meaning of H or lower alkyl,  
 X has the meaning of imino, oxa or thia;  
 Y has the meaning of hydrogene, unsubstituted or substituted aryl, heteroaryl, or unsubstituted  
 5 or substituted cycloalkyl; and  
 Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl,  
 hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated carboxy, al-  
 kanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto,  
 10 sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-  
 sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfo-  
 nyl, whereas, if more than one rest Z is present (m≥2), the substituents Z are equal or different  
 from each other, and wherein the bonds marked with an arrow are single or double bonds; or  
 an N-oxide of said compound, wherein one ore more N-atoms carry an oxygene atom, or a  
 salt thereof,

and/or a compound of genaral formula IV





in which

A has the meaning of group =NR<sup>2</sup>,  
 W has the meaning of oxygen, sulfur, two hydrogen atoms or the group =NR<sup>8</sup>,  
 Z has the meaning of the group =NR<sup>10</sup> or =N-, -N(R<sup>10</sup>)-(CH<sub>2</sub>)<sub>q</sub>-, branched or unbranched  
 C<sub>1-6</sub>-Alkyl or is the group




or A, Z and R<sup>1</sup> together form the group






m, n and o has the meaning of 0 - 3,  
q has the meaning of 1 - 6,  
 $R_a, R_b, R_c, R_d, R_e, R_f$  independently from each other have the meaning of hydrogen,  $C_{1-4}$  alkyl or the group  $=NR^{10}$ , and/ or  $R_a$  and/ or  $R_b$  together with  $R_c$  and or  $R_d$  or  $R_c$  together with  $R_e$  and/ or  $R_f$  form a bound, or up to two of the groups  $R_a-R_f$  form a bridge with each up to 3 C-atoms with  $R^1$  or  $R^2$ ,  
X has the meaning of group  $=NR^9$  or  $=N-$ ,  
Y has the meaning of group  $-(CH_2)_p$ ,  
p has the meaning of integer 1-4,  
 $R^1$  has the meaning of unsubstituted or optionally substituted with one or more of halogene,  $C_{1-6}$ -alkyl, or  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,  
 $R^2$  has the meaning of hydrogen or  $C_{1-6}$ -alkyl, or form a bridge with up to 3 ring atoms with  $R_a-R_f$  together with Z or  $R_1$ ,  
 $R^3$  has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of für halogen,  $C_{1-6}$ -alkyl,  $C_{1-6}$ -alkoxy or hydroxy,  
 $R^4, R^5, R^6$  and  $R^7$  independently from each other have the meaning of hydrogen, halogene or  $C_{1-6}$ -alkoxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogene, or  $R^5$  and  $R^6$  together form the group



$R^8, R^9$  and  $R^{10}$  independently from each other have the meaning of hydrogen or  $C_{1-6}$ -alkyl, as well as their isomers and salts,



and/ or a compound of general formula V




V,

in which


R<sup>1</sup> has the meaning of group



in which R<sup>5</sup> is chloro, bromo or the group -OCH<sub>3</sub>,



in which R<sup>7</sup> is -CH<sub>3</sub> or chloro,




in which R<sup>8</sup> is -CH<sub>3</sub>, fluoro, chloro or -CF<sub>3</sub>

in which R<sup>4</sup> is fluoro, chloro, bromo, -CF<sub>3</sub>, -N=C, -CH<sub>3</sub>, -OCF<sub>3</sub> or -CH<sub>2</sub>OH

in which R<sup>6</sup> is -CH<sub>3</sub> or chloro

R<sup>2</sup> has the meaning of pyridyl or the group



and

10  $R^3$  has the meaning of hydrogen or fluoro, as well as their isomers and salts.

16. Pharmaceutical compositions according to claim 15 which comprise as compound I and/ or II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate

15 17. Pharmaceutical compositions according to claims 1-16 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35 and/ or scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate sTie2, mAB 4301-42-35 and/ or scFv-tTF conjugate, with the proviso that compound I is not identically to compound II.

20 18. Pharmaceutical compositions according to claims 1-17 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35 and/ or scFv-tTF conjugate.

25 19. Pharmaceutical compositions according to claims 1-17 which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate.

20. Pharmaceutical compositions according to claims 1-17 which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35.

30 21. Use of pharmaceutical compositions according to claims 1-20, for the production of a medicament for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

35

40

45

50

55




Fig. 1



European Patent  
Office

# PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

EP 00 25 0194

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	WO 98 35958 A (NOVARTIS ERFINDUNGEN VERWALTUN ; CIBA GEIGY AG (CH); TRAXLER PETER) 20 August 1998 (1998-08-20) * abstract * * page 1, paragraph 1 *	1-15, 21	A61K45/06
A	KOBLIZEK, THOMAS I. ET AL: "Angiopoietin-1 induces sprouting angiogenesis in vitro" CURR. BIOL. (1998), 8(9), 529-532 , XP000972727 * page 531, column 1, paragraph 2 *	1-21	
A	SCHLAEPI, JEAN-MARC ET AL: "Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors." CANCER AND METASTASIS REVIEWS, (1999) VOL. 18, NO. 4, PP. 473-481. PRINT. , XP000972749 * page 477, column 2, paragraph 2 - page 478, column 1, paragraph 1 *	1-21	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			A61K
INCOMPLETE SEARCH			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims</p> <p>Claims searched completely</p> <p>Claims searched incompletely</p> <p>Claims not searched</p> <p>Reason for the limitation of the search</p> <p>see sheet C</p>			
Place of search		Date of completion of the search	Examiner
THE HAGUE		12 January 2001	Leherte, C
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons</p> <p>&amp; : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03 82 (p04c07)



European Patent  
Office

INCOMPLETE SEARCH  
SHEET C

Application Number  
EP 00 25 0194

Claim(s) searched completely:  
17-20

Claim(s) searched incompletely:  
1-16, 21

Reason for the limitation of the search:

Present claims 1-16,21 relate to compounds defined by reference to desirable characteristics or properties, namely :

- " agents which modulates the biological function of one or several of the VEGF/VEGF receptor systems",
- " agents which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems",
- " agents which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems",
- " agents which are targeted to the endothelium",
- " agents which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems",
- " agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of the Angiopoietin/Tie receptor systems",
- " compounds which inhibit receptor tyrosine kinase activity",
- " compounds which inhibit ligand binding to receptors",
- " compounds which inhibit activation of intracellular signal pathways of the receptors",
- " compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor systems",
- " delivery systems, which target cytotoxic agents or coagulation-inducing agents to the endothelium",
- "delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis",
- " compounds of general formula I, IV or V".

The claims cover all compounds having those characteristics, properties or formulas, whereas the application provides support within the meaning of Article 84 EPC and/or disclosure within the meaning of Article 83 EPC for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 84 EPC). An attempt is made to define the compounds by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the pharmaceutical compositions mentioned in the claims 17-20, with due regard to the therapeutic applications mentioned in claim 21.

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 25 0194

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

12-01-2001

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9835958 A	20-08-1998	AU 6621898 A	08-09-1998
		BR 9807685 A	21-03-2000
		CN 1251097 T	19-04-2000
		CZ 9902853 A	17-11-1999
		EP 0970070 A	12-01-2000
		NO 993888 A	11-10-1999
		PL 335113 A	10-04-2000
		SK 109699 A	13-03-2000
		ZA 9801155 A	13-08-1998
<hr/>			

EPO FORM P0469

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82